```
=> fil reg
FILE 'REGISTRY' ENTERED AT 10:06:16 ON 15 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 APR 2004  HIGHEST RN 675103-21-6
DICTIONARY FILE UPDATES:  13 APR 2004  HIGHEST RN 675103-21-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d sta que l47
L25                 STR
```




```
VAR G1=AK/4/6/10/14/19/26/28/30/32/34/37/41/44
NODE ATTRIBUTES:
NSPEC   IS RC     AT   1
CONNECT IS M1  RC AT   1
CONNECT IS M1  RC AT  19
CONNECT IS M1  RC AT  48
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
```

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 46

STEREO ATTRIBUTES: NONE
L27 46016 SEA FILE=REGISTRY CSS FUL L25
L36 STR



VAR G1=AK/4/6/10/14/19/26/28/30/32/34/37/41/44
VAR G2=CH/50
VAR G3=CN/X/AK/4/6/10/14/19
NODE ATTRIBUTES:
CONNECT IS M1 RC AT 19
CONNECT IS M1 RC AT 48
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 48

STEREO ATTRIBUTES: NONE
L38 4398 SEA FILE=REGISTRY SUB=L27 CSS FUL L36
L45 STR




```
VAR G1=AK/4/6/10/14/19/26/28/30/32/34/37/41/44
VAR G2=70/57/59/61/63/69/55
REP G3=(0-1) AK
REP G4=(0-2) 53
NODE ATTRIBUTES:
NSPEC   IS RC     AT   1
CONNECT IS M1  RC AT   1
CONNECT IS M1  RC AT  48
CONNECT IS M1  RC AT  53
CONNECT IS M1  RC AT  54
CONNECT IS M1  RC AT  55
CONNECT IS M1  RC AT  56
CONNECT IS M1  RC AT  58
CONNECT IS M1  RC AT  60
CONNECT IS M1  RC AT  62
CONNECT IS M1  RC AT  67
CONNECT IS M1  RC AT  70
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  65

STEREO ATTRIBUTES: NONE
L47         1307 SEA FILE=REGISTRY SUB=L38 CSS FUL L45

100.0% PROCESSED   4398 ITERATIONS                    1307 ANSWERS
SEARCH TIME: 00.00.01


=> d his
```

```
     (FILE 'HOME' ENTERED AT 08:23:26 ON 15 APR 2004)
               SET COST OFF

     FILE 'HCAPLUS' ENTERED AT 08:23:44 ON 15 APR 2004
L1             1 S WO2000-AU680/AP,PRN
               E WU W/AU
L2           366 S E3,E28,E29
               E WU WEN/AU
L3           102 S E3,E115
               E WU WENY/AU
L4             2 S E6
               E WATSON K/AU
L5           272 S E3-E18
               E WATSON KEITH /AU
L6           134 S E3-E14
               E MCCONNELL D/AU
L7           116 S E3-E8,E13,E14
               E MC CONNELL D/AU
               E JIN B/AU
L8           307 S E3-E14
L9            21 S E81
               E KRIPPNER G/AU
L10           21 S E3-E5
               E BIOTA/PA,CS
L11           54 S E3-E37
               SEL RN L1

     FILE 'REGISTRY' ENTERED AT 08:26:50 ON 15 APR 2004
L12          197 S E1-E197
L13           23 S L12 NOT OXIME
L14            5 S L13 AND (C20H22CLN5O2 OR C18H21N3O3 OR C22H29N3O4S OR C21H27N
L15           18 S L13 NOT L14
L16          179 S L12 NOT L15
L17            2 S L16 AND (C9H11NO2 OR C7H7NO)
L18          177 S L16 NOT L17
               SAV L18 CRANE018/A
L19            STR
L20            0 S L19 CSS SAM
L21            0 S L19 SAM
L22            STR L19
L23            0 S L22 CSS SAM
L24            0 S L22 SAM
L25            STR L22
L26           50 S L25 CSS SAM
L27        46016 S L25 CSS FUL
               SAV TEMP L27 CRANE018A/A
L28          174 S L12 AND L27
L29            3 S L18 NOT L28
L30            2 S L29 NOT C16H21NO2
L31          176 S L28,L30
L32            STR L25
L33            0 S L32 CSS SAM SUB=L27
L34            STR L32
L35            0 S L34 CSS SAM SUB=L27
L36            STR L34
L37           50 S L36 CSS SAM SUB=L27
L38         4398 S L36 CSS FUL SUB=L27
               SAV TEMP L38 CRANE018B/A
L39            STR L36
L40            STR L39
L41            1 S L40 CSS SAM SUB=L27
L42           18 S L40 CSS FUL SUB=L27
```

L42 = FY 69, chem
X^2 [illegible]
AR
No relevant hits

L31 = applicants

```
                SAV L42 TEMP CRANE018C/A
L43             STR L25
L44           0 S L43 FUL SUB=L42
                SAV L44 CRANE018D/A
L45             STR L25
L46          50 S L45 CSS SAM SUB=L38
L47        1307 S L45 CSS FUL SUB=L38
                SAV L47 TEMP CRANE018E/A
L48        1142 S L47 NOT L12

     FILE 'HCAPLUS' ENTERED AT 09:21:59 ON 15 APR 2004
L49           2 S L31
L50           2 S L49 AND L1-L11
L51         391 S L48
L52         363 S L51 AND (PD<=19990618 OR PRY<=19990618 OR AY<=19990618)
                E RHINOVIR/CT
                E E4+ALL
L53        1306 S E7,E6+NT
                E E5+ALL
L54         736 S E6,E5
L55       10479 S E5+NT
L56           0 S L52 AND L53
L57           0 S L52 AND L54
L58           0 S L52 AND L55
L59           1 S L51 AND L53-L55
L60           1 S L51 AND (?RHINOVIR? OR ?PICORNAVIR?)
L61           2 S L50,L59,L60
L62          41 S L52 AND (?VIRUS? OR ?VIRAL? OR ?VIRUC?)
                E ANTIVIRAL/CT
                E E5+ALL
L63       43597 S E10,E11,E9+NT
L64       10840 S E20
                E VIRUS INFECTION/CT
                E VIRA INFECTION/CT
                E VIRAL INFECTION/CT
                E E3+ALL
L65       10840 S E2
L66          42 S L51 AND L63-L65
L67          38 S L52 AND L66
L68          42 S L62,L67
                E VIRUS, ANIMAL/CT
L69      112431 S E3
                E E3+ALL
                E E2+ALL
L70         7236 S E5,E3
L71           10 S L52 AND L69-L70
L72           42 S L68,L71
L73            0 S L72 AND (ENTEROVIR? OR COXSA
L74          225 S L48 (L) (THU OR BAC OR DMA O
L75           34 S L74 AND L72
L76           20 S L75 NOT P/DT
L77           14 S L75 NOT L76
L78            8 S L72 NOT L75
L79           42 S L72 AND L74-L78
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 09:52:05 ON 15
L80           75 S E1-E75
L81            4 S L80 AND C12H14N6O2
L82            3 S L80 AND (C17H14FN3O OR C17H15N3OS OR C18H15N3O2S)

     FILE 'HCAPLUS' ENTERED AT 10:03:37 ON 15 APR 2004
L83            6 S L81 OR L82
```

L51, L52 = only "good" hits for L79 which read on structure 9 claim 1

References for those in L87

L61 = applicants

```
L84             4 S L83 AND (PY<=1999 OR PRY<=1999 OR AY<=1999)
L85             2 S L84 AND L53-L55,L63-L65,L69,L70
L86             3 S L84 AND (?VIRUS? OR ?VIRAL? OR ?VIRUC? OR ENTEROVIR? OR COXSA
L87             4 S L84-L86

     FILE 'REGISTRY' ENTERED AT 10:06:16 ON 15 APR 2004

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 10:06:36 ON 15 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 15 Apr 2004  VOL 140 ISS 16
FILE LAST UPDATED: 14 Apr 2004  (20040414/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d all tot l61 hitstr

L61  ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2004 ACS on STN
AN   2003:463807  HCAPLUS
DN   139:173249
ED   Entered STN:  18 Jun 2003
TI   An Orally Bioavailable Oxime Ether Capsid Binder with Potent Activity
     against Human Rhinovirus
AU   Watson, Keith G.; Brown, Renee N.; Cameron, Rachel; Chalmers,
     David K.; Hamilton, Stephanie; Jin, Betty; Krippner, Guy
     Y.; Luttick, Angela; McConnell, Darryl B.; Reece, Phillip
     A.; Ryan, Jane; Stanislawski, Pauline C.; Tucker, Simon P.; Wu,
     Wen-Yang; Barnard, Dale L.; Sidwell, Robert W.
CS   Biota Chemistry Laboratory, School of Chemistry, Monash University,
     Victoria, 3800, Australia
SO   Journal of Medicinal Chemistry (2003), 46(15), 3181-3184
     CODEN: JMCMAR; ISSN: 0022-2623
PB   American Chemical Society
DT   Journal
LA   English
CC   1-5 (Pharmacology)
GI
```



I

```
AB   A series of capsid-binding compds. was screened against human
```

rhinovirus (HRV) using a CPE based assay. The Et oxime ether (I) was found to have outstanding anti-HRV activity (median IC50 4.75 ng/mL), and unlike the equivalent Et ester compound, Pirodavir, it has good oral bioavailability, making it a promising development candidate. I illustrates that an oxime ether group can act as a metabolically stable bioisostere for an ester functionality.

ST oral bioavailable oxime ether antiviral human **Rhinovirus**

IT Virion structure
(capsid; orally bioavailable oxime ether capsid binder with potent activity against human **Rhinovirus**)

IT Antiviral agents
Bioavailability
Human
Human rhinovirus
(orally bioavailable oxime ether capsid binder with potent activity against human **Rhinovirus**)

IT **577792-16-6P**
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(orally bioavailable oxime ether capsid binder with potent activity against human **Rhinovirus**)

IT 124436-59-5P, Pirodavir 124437-42-9P 124437-50-9P **314062-82-3P** **314062-85-6P** **314062-87-8P** **314062-88-9P** **314062-89-0P** **314062-90-3P** **314062-91-4P** **314062-93-6P** 577792-11-1P 577792-12-2P **577792-13-3P** 577792-14-4P 577792-15-5P 577792-17-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(orally bioavailable oxime ether capsid binder with potent activity against human **Rhinovirus**)

IT 120-47-8, Ethyl 4-hydroxybenzoate 141-30-0 622-26-4, 4-Piperidineethanol 1121-79-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(orally bioavailable oxime ether capsid binder with potent activity against human **Rhinovirus**)

IT 124438-51-3P 124438-52-4P 124438-66-0P 124438-73-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(orally bioavailable oxime ether capsid binder with potent activity against human **Rhinovirus**)

IT 577792-10-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(orally bioavailable oxime ether capsid binder with potent activity against human **Rhinovirus**)

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Andries, K; Antimicrob Agents Chemother 1992, V36, P100 HCAPLUS
(2) Andries, K; Antiviral Res 1991, V16, P213 HCAPLUS
(3) Andries, K; The Search for Antiviral Drugs 1993, P179
(4) Anon; WO 0078746 2001 HCAPLUS
(5) Arruda, E; Antiviral Chemotherapy 1995, P321
(6) Bromidge, S; J Med Chem 1997, V40, P4265 HCAPLUS
(7) Burger, A; Prog Drug Res 1991, V37, P287 HCAPLUS
(8) Diana, G; Antiviral Chem Chemother 1997, V8, P401 HCAPLUS
(9) Diana, G; J Comput-Aided Mol Design 1993, V7, P325 HCAPLUS
(10) Dragovich, P; J Med Chem 1999, V42, P1213 HCAPLUS
(11) Giranda, V; Acta Crystallogr 1995, VD51, P496
(12) Giranda, V; Structure-Based Drug Design 1997, P487
(13) Hadfield, A; Proc Natl Acad Sci U S A 1999, V96, P14730 HCAPLUS
(14) Hayden, F; Abstracts of 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract 1161 2000

(15) Hayden, F; Antimicrob Agents Chemother 1992, V36, P727 MEDLINE
(16) Hayden, F; Antimicrob Agents Chemother 1995, V39, P290 HCAPLUS
(17) Hayden, F; www.viropharma.com/healthcare/clinical.html
(18) Karabatsos, G; Tetrahedron 1967, V23, P1079 HCAPLUS
(19) Lipinski, C; Annu Rep Med Chem 1986, V21, P283 HCAPLUS
(20) Makela, M; J Clin Microbiol 1998, V36, P539 MEDLINE
(21) McKinlay, M; Annu Rev Microbiol 1992, V46, P635 HCAPLUS
(22) Oren, D; J Mol Biol 1996, V259, P120 HCAPLUS
(23) Patani, G; Chem Rev 1996, V96, P3147 HCAPLUS
(24) Sidwell, R; Appl Microbiol 1976, V22, P797
(25) Stokbroekx, R; US 4992433 1990 HCAPLUS
(26) Tebbe, M; J Med Chem 1997, V40, P3937 HCAPLUS
(27) Turner, R; Pediatr Ann 1998, V27, P790 MEDLINE

IT **577792-16-6P**
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(orally bioavailable oxime ether capsid binder with potent activity against human **Rhinovirus**)
RN 577792-16-6 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime, [C(E)]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **314062-82-3P 314062-85-6P 314062-87-8P**
314062-88-9P 314062-89-0P 314062-90-3P
314062-91-4P 314062-93-6P 577792-13-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(orally bioavailable oxime ether capsid binder with potent activity against human **Rhinovirus**)
RN 314062-82-3 HCAPLUS
CN Ethanone, 1-[4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]phenyl]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314062-85-6 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314062-87-8 HCAPLUS
CN Ethanone, 1-[4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]phenyl]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314062-88-9 HCAPLUS
CN 1-Propanone, 1-[4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]phenyl]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314062-89-0 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-propyloxime (9CI) (CA INDEX NAME)



RN 314062-90-3 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-(1-methylethyl)oxime (9CI) (CA INDEX NAME)



RN 314062-91-4 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314062-93-6 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-(phenylmethyl)oxime (9CI) (CA INDEX NAME)



RN 577792-13-3 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime, [C(E)]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L61 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:911241 HCAPLUS
DN 134:71606
ED Entered STN: 29 Dec 2000
TI Preparation of (heterocyclyl)alkoxy benzaldehyde oximes as antiviral agents
IN **Wu, Wen-Yang; Watson, Keith; Mcconnell, Darryl ; Jin, Betty; Krippner, Guy**
PA **Biota Scientific Management Pty. Ltd., Australia**
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D401-04
ICS C07D403-04; C07D261-08; C07D237-10; C07D417-04; A61K031-501; A61K031-42; A61K031-50; A61K031-4453; A61P031-12
CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 10
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000078746	A1	20001228	WO 2000-AU680	20000616 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1187827	A1	20020320	EP 2000-936548	20000616 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2003502418	T2	20030121	JP 2001-504912	20000616 <--
PRAI	AU 1999-1054	A	19990618		
	WO 2000-AU680	W	20000616 <--		
OS	MARPAT 134:71606				
GI					



II

AB The title compds. Het-A-Alk-W-Ar-C(X2):NOX1 [I; Het = (un)substituted 5-6 membered monocyclic heterocyclic radical, (un)substituted 9-10 membered bicyclic heterocyclic radical; A = O, S, NH, etc.; Alk = alkylene, a bond; W = O, S, OCH2, etc.; Ar = (un)substituted 5-6 membered monocyclic aryl, (un)substituted 9-10 membered bicyclic aryl; X1 = alkyl, alkenyl, alkynyl, etc.; X2 = H, CN, F, etc.], useful in the treatment picornavirus infections in mammals, were prepared Thus, reacting 4-{2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy}benzaldehyde in EtOH with a solution of EtONH2 in H2O afforded 44% O-ethyloxime II. Biol. data (activity against, e.g., HRV-1A, HRV-2, HRV-14, enterovirus 70, Coxsackie A21) for compds. I was given.

ST benzaldehyde oxime heterocyclylalkoxy prepn antiviral picornavirus; rhinovirus antiviral benzaldehyde oxime heterocyclylalkoxy prepn; enterovirus antiviral benzaldehyde oxime heterocyclylalkoxy prepn; coxsackievirus antiviral benzaldehyde oxime heterocyclylalkoxy prepn

IT Antiviral agents
Enterovirus
Human coxsackievirus A21
Human rhinovirus 14
Human rhinovirus 2
Picornaviridae
(preparation of (heterocyclyl)alkoxy benzaldehyde oximes as antiviral agents)

IT Human rhinovirus
(type 1A; preparation of (heterocyclyl)alkoxy benzaldehyde oximes as antiviral agents)

IT **314062-80-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of (heterocyclyl)alkoxy benzaldehyde oximes as antiviral agents)

IT **314062-79-8P 314062-81-2P 314062-82-3P**

314062-83-4P 314062-84-5P 314062-85-6P
314062-86-7P 314062-87-8P 314062-88-9P
314062-89-0P 314062-90-3P 314062-91-4P
314062-92-5P 314062-93-6P 314062-94-7P
314062-95-8P 314062-96-9P 314062-97-0P
314062-98-1P 314063-00-8P 314063-01-9P
314063-02-0P 314063-04-2P 314063-05-3P
314063-06-4P 314063-07-5P 314063-08-6P
314063-09-7P 314063-10-0P 314063-11-1P
314063-12-2P 314063-13-3P 314063-15-5P
314063-16-6P 314063-17-7P 314063-18-8P
314063-19-9P 314063-20-2P 314063-22-4P
314063-23-5P 314063-25-7P 314063-26-8P
314063-27-9P 314063-28-0P 314063-32-6P
314063-33-7P 314063-35-9P 314063-36-0P
314063-37-1P 314063-38-2P 314063-39-3P
314063-40-6P 314063-41-7P 314063-42-8P
314063-43-9P 314063-44-0P 314063-45-1P
314063-46-2P 314063-47-3P 314063-48-4P
314063-51-9P 314063-52-0P 314063-53-1P
314063-55-3P 314063-57-5P 314063-59-7P
314063-60-0P 314063-61-1P 314063-64-4P
314063-66-6P 314063-67-7P 314063-68-8P
314063-69-9P 314063-70-2P 314063-71-3P
314063-72-4P 314063-73-5P 314063-74-6P
314063-75-7P 314063-76-8P 314063-77-9P
314063-78-0P 314063-79-1P 314063-80-4P
314063-81-5P 314063-82-6P 314063-83-7P
314063-84-8P 314063-85-9P 314063-86-0P
314063-87-1P 314063-89-3P 314063-90-6P
314063-91-7P 314063-95-1P 314063-96-2P
314063-98-4P 314063-99-5P 314064-01-2P
314064-03-4P 314064-04-5P 314064-05-6P
314064-06-7P 314064-07-8P 314064-08-9P
314064-09-0P 314064-13-6P 314064-14-7P
314064-15-8P 314064-16-9P 314064-17-0P
314064-18-1P 314064-19-2P 314064-20-5P
314064-21-6P 314064-22-7P 314064-23-8P
314064-24-9P 314064-25-0P 314064-26-1P
314064-27-2P 314064-28-3P 314064-29-4P
314064-30-7P 314064-31-8P 314064-32-9P
314064-33-0P 314064-34-1P 314064-36-3P
314064-40-9P 314064-44-3P 314064-46-5P
314064-47-6P 314064-48-7P 314064-49-8P
314064-50-1P 314064-51-2P 314064-52-3P
314064-53-4P 314064-54-5P 314064-55-6P
314064-56-7P 314064-57-8P 314064-58-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (heterocyclyl)alkoxy benzaldehyde oximes as antiviral agents)

IT 314062-99-2 314063-03-1 314063-14-4
314063-21-3 314063-24-6 314063-29-1
314063-30-4 314063-31-5 314063-34-8
314063-49-5 314063-50-8 314063-54-2
314063-56-4 314063-58-6 314063-62-2
314063-63-3 314063-65-5 314063-88-2
314063-92-8 314063-93-9 314063-94-0
314063-97-3 314064-00-1 314064-02-3
314064-10-3 314064-11-4 314064-12-5
314064-35-2 314064-38-5 314064-42-1
314255-60-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of (heterocyclyl)alkoxy benzaldehyde oximes as antiviral agents)

IT 123-08-0, 4-Hydroxybenzaldehyde 141-30-0 622-26-4, 4-Piperidineethanol 932-90-1, Benzaldehyde oxime 2508-29-4, 5-Amino-1-pentanol 41731-52-6, Ethyl 2-chloro-4-thiazolecarboxylate 54044-79-0, 2-Bromo-5-methyl-1,3,4-thiadiazole 124437-50-9 124438-51-3 124438-73-9 314064-67-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of (heterocyclyl)alkoxy benzaldehyde oximes as antiviral agents)

IT 5198-85-6P 113079-60-0P 314064-59-0P 314064-60-3P 314064-61-4P 314064-62-5P 314064-63-6P 314064-64-7P 314064-65-8P 314064-66-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (heterocyclyl)alkoxy benzaldehyde oximes as antiviral agents)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bayer Ag; EP 290906 A 1988 HCAPLUS
(2) Bayer Aktiengesellschaft; US 4472416 A 1984 HCAPLUS
(3) Kumiai Chem Ind Co Ltd; JP 8081314 A 1996
(4) Malamas; J Med Chem 1996, V39(1), P237 HCAPLUS
(5) Starling; Indian Journal of chemistry 1977, V15(8), P715 HCAPLUS
(6) Strupczewski; J Med Chem 1995, V38(7), P1119 HCAPLUS
(7) Teijin Limited; WO 9001874 1990 HCAPLUS
(8) Teijin Ltd; JP 05320117 A 1993 HCAPLUS

IT **314062-80-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of (heterocyclyl)alkoxy benzaldehyde oximes as antiviral agents)

RN 314062-80-1 HCAPLUS

CN Benzaldehyde, 4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



IT **314062-79-8P 314062-81-2P 314062-82-3P**
314062-83-4P 314062-84-5P 314062-85-6P
314062-86-7P 314062-87-8P 314062-88-9P
314062-89-0P 314062-90-3P 314062-91-4P
314062-92-5P 314062-93-6P 314062-94-7P
314062-95-8P 314062-96-9P 314062-97-0P
314062-98-1P 314063-00-8P 314063-01-9P
314063-02-0P 314063-04-2P 314063-05-3P
314063-06-4P 314063-07-5P 314063-08-6P
314063-09-7P 314063-10-0P 314063-11-1P
314063-12-2P 314063-13-3P 314063-15-5P
314063-16-6P 314063-17-7P 314063-18-8P
314063-19-9P 314063-20-2P 314063-22-4P
314063-23-5P 314063-25-7P 314063-26-8P
314063-27-9P 314063-28-0P 314063-32-6P

314063-33-7P 314063-35-9P 314063-36-0P
314063-37-1P 314063-38-2P 314063-39-3P
314063-40-6P 314063-41-7P 314063-42-8P
314063-43-9P 314063-44-0P 314063-45-1P
314063-46-2P 314063-47-3P 314063-48-4P
314063-51-9P 314063-52-0P 314063-53-1P
314063-55-3P 314063-57-5P 314063-59-7P
314063-60-0P 314063-61-1P 314063-64-4P
314063-66-6P 314063-67-7P 314063-68-8P
314063-69-9P 314063-70-2P 314063-71-3P
314063-72-4P 314063-73-5P 314063-74-6P
314063-75-7P 314063-76-8P 314063-77-9P
314063-78-0P 314063-79-1P 314063-80-4P
314063-81-5P 314063-82-6P 314063-83-7P
314063-84-8P 314063-85-9P 314063-86-0P
314063-87-1P 314063-89-3P 314063-90-6P
314063-91-7P 314063-95-1P 314063-96-2P
314063-98-4P 314063-99-5P 314064-01-2P
314064-03-4P 314064-04-5P 314064-05-6P
314064-06-7P 314064-07-8P 314064-08-9P
314064-09-0P 314064-13-6P 314064-14-7P
314064-15-8P 314064-16-9P 314064-17-0P
314064-18-1P 314064-19-2P 314064-20-5P
314064-21-6P 314064-22-7P 314064-23-8P
314064-24-9P 314064-25-0P 314064-26-1P
314064-27-2P 314064-28-3P 314064-29-4P
314064-30-7P 314064-31-8P 314064-32-9P
314064-33-0P 314064-34-1P 314064-36-3P
314064-40-9P 314064-44-3P 314064-46-5P
314064-47-6P 314064-48-7P 314064-49-8P
314064-50-1P 314064-51-2P 314064-52-3P
314064-53-4P 314064-54-5P 314064-55-6P
314064-56-7P 314064-57-8P 314064-58-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (heterocyclyl)alkoxy benzaldehyde oximes as antiviral agents)

RN 314062-79-8 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314062-81-2 HCAPLUS
CN Ethanone, 1-[4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]phenyl]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314062-82-3 HCAPLUS
CN Ethanone, 1-[4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]phenyl]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314062-83-4 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-3-methoxy-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314062-84-5 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-3,5-dimethoxy-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314062-85-6 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314062-86-7 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314062-87-8 HCAPLUS
CN Ethanone, 1-[4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]phenyl]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314062-88-9 HCAPLUS
CN 1-Propanone, 1-[4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]phenyl]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314062-89-0 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-propyloxime (9CI) (CA INDEX NAME)



RN 314062-90-3 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-(1-methylethyl)oxime (9CI) (CA INDEX NAME)



RN 314062-91-4 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314062-92-5 HCAPLUS
CN Acetonitrile, [[[[4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]phenyl]methylene]amino]oxy]- (9CI) (CA INDEX NAME)



RN 314062-93-6 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-(phenylmethyl)oxime (9CI) (CA INDEX NAME)



RN 314062-94-7 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-3,5-

dimethyl-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314062-95-8 HCAPLUS
CN Ethanone, 1-[4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-3-methoxyphenyl]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314062-96-9 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-[2-[2-(ethyldioxy)ethoxy]ethyl]oxime (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 314062-97-0 HCAPLUS
CN Benzaldehyde, 4-[2-[1-[6-(2,2,2-trifluoroethoxy)-3-pyridazinyl]-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314062-98-1 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-methoxy-3-pyridazinyl)-4-piperidinyl]ethoxy]-,

O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-00-8 HCAPLUS
CN Benzaldehyde, 4-[[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]methoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-01-9 HCAPLUS
CN Benzaldehyde, 4-[3-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]propoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-02-0 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-3-methoxy-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-04-2 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-3-nitro-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-05-3 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-2-hydroxy-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-06-4 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-3-methyl-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-07-5 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-3-methyl-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314063-08-6 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-3-methyl-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-09-7 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-3,5-dimethyl-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-10-0 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-11-1 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-2-methoxy-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-12-2 HCAPLUS
CN Benzaldehyde, 3-methyl-4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-13-3 HCAPLUS
CN Benzaldehyde, 3-methyl-4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-15-5 HCAPLUS
CN Benzaldehyde, 3-methyl-4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-propyloxime (9CI) (CA INDEX NAME)



RN 314063-16-6 HCAPLUS
CN Benzaldehyde, 4-[[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]oxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-17-7 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-phenyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-18-8 HCAPLUS
CN 1-Propanone, 1-[4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]phenyl]-, O-ethyloxime, (1Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 314063-19-9 HCAPLUS
CN Benzaldehyde, 4-[2-[1-[6-(trifluoromethyl)-3-pyridazinyl]-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-20-2 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-(2,2,2-trifluoroethyl)oxime (9CI) (CA INDEX NAME)



RN 314063-22-4 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-propyloxime (9CI) (CA INDEX NAME)



RN 314063-23-5 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-(2-methoxyethyl)oxime (9CI) (CA INDEX NAME)



RN 314063-25-7 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-2-propynyloxime (9CI) (CA INDEX NAME)



RN 314063-26-8 HCAPLUS
CN Benzaldehyde, 4-[3-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]propoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-27-9 HCAPLUS
CN Benzaldehyde, 4-[3-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]propoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-28-0 HCAPLUS
CN Benzaldehyde, 4-[3-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]propoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-32-6 HCAPLUS
CN 3-Pyridazinecarboxaldehyde, 6-[4-[2-[4-[(ethoxyimino)methyl]phenoxy]ethyl]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 314063-33-7 HCAPLUS
CN Benzaldehyde, 4-[2-[1-[6-(hydroxymethyl)-3-pyridazinyl]-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-35-9 HCAPLUS
CN Benzaldehyde, 3-hydroxy-4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-36-0 HCAPLUS
CN Benzaldehyde, 2,6-dimethyl-4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-37-1 HCAPLUS
CN Benzaldehyde, 2,6-dimethyl-4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-38-2 HCAPLUS
CN Benzaldehyde, 2-methoxy-4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-39-3 HCAPLUS
CN Benzaldehyde, 2-methyl-4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-40-6 HCAPLUS
CN Benzaldehyde, 2-methyl-4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-41-7 HCAPLUS
CN Benzaldehyde, 2,5-dimethyl-4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-42-8 HCAPLUS
CN Benzaldehyde, 2,5-dimethyl-4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-43-9 HCAPLUS
CN Benzaldehyde, 2,3-dimethyl-4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-44-0 HCAPLUS
CN Benzaldehyde, 2,3-dimethyl-4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-45-1 HCAPLUS
CN 3-Pyridazinecarboxaldehyde, 6-[4-[2-[4-[(ethoxyimino)methyl]phenoxy]ethyl]-1-piperidinyl]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-46-2 HCAPLUS
CN Benzaldehyde, 3-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-47-3 HCAPLUS
CN Benzaldehyde, 3-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-4-methoxy-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-48-4 HCAPLUS
CN Benzaldehyde, 3-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-5-hydroxy-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-51-9 HCAPLUS
CN Benzaldehyde, 3-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-52-0 HCAPLUS
CN Benzaldehyde, 3-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-53-1 HCAPLUS
CN Benzaldehyde, 3-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314063-55-3 HCAPLUS
CN Benzaldehyde, 3-[[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]methoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-57-5 HCAPLUS
CN Benzaldehyde, 3-[[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]methoxy]-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314063-59-7 HCAPLUS
CN Benzaldehyde, 3-[3-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]propoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-60-0 HCAPLUS
CN Benzaldehyde, 3-[3-[1-(6-methoxy-3-pyridazinyl)-4-piperidinyl]propoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-61-1 HCAPLUS
CN Benzaldehyde, 3-[3-[1-(6-methoxy-3-pyridazinyl)-4-piperidinyl]propoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-64-4 HCAPLUS
CN Benzaldehyde, 3-[3-[1-(3-pyridazinyl)-4-piperidinyl]propoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-66-6 HCAPLUS
CN 1H-Inden-1-one, 2,3-dihydro-4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-67-7 HCAPLUS
CN Benzaldehyde, 3,5-dimethyl-4-[3-(3-methyl-5-isoxazolyl)propoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



p 2/2

RN 314063-68-8 HCAPLUS
CN Benzaldehyde, 3,5-dimethyl-4-[3-(3-methyl-5-isoxazolyl)propoxy]-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314063-69-9 HCAPLUS
CN Benzaldehyde, 3,5-dimethyl-4-[3-(3-methyl-5-isoxazolyl)propoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-70-2 HCAPLUS
CN Benzaldehyde, 3,5-dimethyl-4-[3-(3-methyl-5-isoxazolyl)propoxy]-, O-(phenylmethyl)oxime (9CI) (CA INDEX NAME)



RN 314063-71-3 HCAPLUS
CN Benzaldehyde, 4-[3-(3-methyl-5-isoxazolyl)propoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-72-4 HCAPLUS

CN Ethanone, 1-[3,5-dimethyl-4-[3-(3-methyl-5-isoxazolyl)propoxy]phenyl]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-73-5 HCAPLUS
CN Benzaldehyde, 3,5-dimethyl-4-[3-(3-methyl-5-isoxazolyl)propoxy]-, O-propyloxime (9CI) (CA INDEX NAME)



RN 314063-74-6 HCAPLUS
CN Acetonitrile, [[[[3,5-dimethyl-4-[3-(3-methyl-5-isoxazolyl)propoxy]phenyl]methylene]amino]oxy]- (9CI) (CA INDEX NAME)



RN 314063-75-7 HCAPLUS
CN Benzaldehyde, 3,5-dimethyl-4-[3-(3-methyl-5-isoxazolyl)propoxy]-, O-2-propynyloxime (9CI) (CA INDEX NAME)



RN 314063-76-8 HCAPLUS
CN Benzaldehyde, 3,5-dimethyl-4-[[6-(3-methyl-5-isoxazolyl)hexyl]oxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-77-9 HCAPLUS

CN Benzaldehyde, 3,5-dimethyl-4-[[7-(3-methyl-5-isoxazolyl)heptyl]oxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-78-0 HCAPLUS
CN Benzaldehyde, 3,5-dimethyl-4-[[5-(3-methyl-5-isoxazolyl)pentyl]oxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-79-1 HCAPLUS
CN Benzaldehyde, 3,5-dimethyl-4-[4-(3-methyl-5-isoxazolyl)butoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-80-4 HCAPLUS
CN Benzaldehyde, 3,5-dimethyl-4-[3-(3-methyl-5-isoxazolyl)propoxy]-, O-(2,2,2-trifluoroethyl)oxime (9CI) (CA INDEX NAME)



RN 314063-81-5 HCAPLUS
CN Benzaldehyde, 3,5-dimethyl-4-[3-(3-methyl-5-isoxazolyl)propoxy]-, O-(2-ethoxyethyl)oxime (9CI) (CA INDEX NAME)



RN 314063-82-6 HCAPLUS

CN Benzaldehyde, 3,5-dimethyl-4-[3-(3-methyl-5-isoxazolyl)propoxy]-, O-(2-oxopropyl)oxime (9CI) (CA INDEX NAME)



RN 314063-83-7 HCAPLUS
CN Benzaldehyde, 3,5-dimethyl-4-[3-(3-phenyl-5-isoxazolyl)propoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-84-8 HCAPLUS
CN Benzaldehyde, 4-[3-(3-ethyl-5-isoxazolyl)propoxy]-3,5-dimethyl-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-85-9 HCAPLUS
CN Benzaldehyde, 3,5-dimethyl-4-[3-(3-propyl-5-isoxazolyl)propoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-86-0 HCAPLUS
CN Benzaldehyde, 4-[2-(3-ethyl-5-isoxazolyl)ethoxy]-3,5-dimethyl-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-87-1 HCAPLUS
CN Benzaldehyde, 3,5-dimethyl-4-[3-(3-methyl-5-isoxazolyl)propoxy]-, O-(2-fluoroethyl)oxime (9CI) (CA INDEX NAME)



RN 314063-89-3 HCAPLUS
CN Benzaldehyde, 4-[4-(3-ethyl-5-isoxazolyl)butoxy]-3,5-dimethyl-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-90-6 HCAPLUS
CN Benzaldehyde, 3,5-dimethyl-4-[4-(3-propyl-5-isoxazolyl)butoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-91-7 HCAPLUS
CN Benzaldehyde, 4-[2-[4-(6-chloro-3-pyridazinyl)-1-piperazinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-95-1 HCAPLUS
CN Benzaldehyde, 4-[2-[4-(6-methyl-3-pyridazinyl)-1-piperazinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-96-2 HCAPLUS
CN Benzaldehyde, 4-[2-[4-(6-methyl-3-pyridazinyl)-1-piperazinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-98-4 HCAPLUS
CN Benzaldehyde, 3-[2-[4-(6-methyl-3-pyridazinyl)-1-piperazinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-99-5 HCAPLUS
CN Benzaldehyde, 3-[2-[4-(6-methyl-3-pyridazinyl)-1-piperazinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-01-2 HCAPLUS
CN Benzaldehyde, 4-[2-[4-(6-chloro-3-pyridazinyl)-1-piperazinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314064-03-4 HCAPLUS
CN Benzaldehyde, 3-[2-[4-(6-chloro-3-pyridazinyl)-1-piperazinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314064-04-5 HCAPLUS
CN Benzaldehyde, 3-[2-[4-(6-chloro-3-pyridazinyl)-1-piperazinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-05-6 HCAPLUS
CN Benzaldehyde, 3-[2-[4-(6-chloro-3-pyridazinyl)-1-piperazinyl]ethoxy]-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314064-06-7 HCAPLUS
CN Benzaldehyde, 4-[2-[4-(6-methyl-3-pyridazinyl)-1-piperazinyl]ethoxy]-, O-propyloxime (9CI) (CA INDEX NAME)



RN 314064-07-8 HCAPLUS
CN Benzaldehyde, 3-[2-[4-(6-methyl-3-pyridazinyl)-1-piperazinyl]ethoxy]-, O-propyloxime (9CI) (CA INDEX NAME)



RN 314064-08-9 HCAPLUS
CN Benzaldehyde, 3-[2-[4-(6-chloro-3-pyridazinyl)-1-piperazinyl]ethoxy]-, O-propyloxime (9CI) (CA INDEX NAME)



RN 314064-09-0 HCAPLUS
CN Benzaldehyde, 4-[[1-(6-chloro-3-pyridazinyl)-3-piperidinyl]methoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-13-6 HCAPLUS
CN Benzaldehyde, 4-[3-[1-(6-chloro-3-pyridazinyl)-3-piperidinyl]propoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-14-7 HCAPLUS
CN Benzaldehyde, 3-[3-[1-[6-(trifluoromethyl)-3-pyridazinyl]-3-piperidinyl]propoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314064-15-8 HCAPLUS
CN Benzaldehyde, 3-[3-[1-[6-(trifluoromethyl)-3-pyridazinyl]-3-piperidinyl]propoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-16-9 HCAPLUS
CN Benzaldehyde, 3-[3-[1-(6-methyl-3-pyridazinyl)-3-piperidinyl]propoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314064-17-0 HCAPLUS
CN Benzaldehyde, 3-[3-[1-(6-methyl-3-pyridazinyl)-3-piperidinyl]propoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-18-1 HCAPLUS
CN Benzaldehyde, 3-[[1-(6-chloro-3-pyridazinyl)-3-piperidinyl]methoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-19-2 HCAPLUS
CN Benzaldehyde, 4-[[1-[6-(trifluoromethyl)-3-pyridazinyl]-3-piperidinyl]methoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-20-5 HCAPLUS
CN Benzaldehyde, 3-[[1-[6-(trifluoromethyl)-3-pyridazinyl]-3-piperidinyl]methoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314064-21-6 HCAPLUS
CN Benzaldehyde, 3-[[1-[6-(trifluoromethyl)-3-pyridazinyl]-3-piperidinyl]methoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-22-7 HCAPLUS
CN Benzaldehyde, 4-[2-[1-[5-(trifluoromethyl)-2-pyridinyl]-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-23-8 HCAPLUS
CN Benzaldehyde, 4-[2-[4-(5-chloropyrazinyl)-1-piperazinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-24-9 HCAPLUS
CN Benzaldehyde, 4-[2-[1-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314064-25-0 HCAPLUS
CN Benzaldehyde, 4-[2-[1-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-26-1 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(5-methyl-1,3,4-thiadiazol-2-yl)-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314064-27-2 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(5-methyl-1,3,4-thiadiazol-2-yl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-28-3 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(5-chloropyrazinyl)-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314064-29-4 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(5-chloropyrazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-30-7 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-methyl-2-pyridinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-31-8 HCAPLUS
CN 4-Thiazolecarboxylic acid, 2-[4-[2-[4-[(methoxyimino)methyl]phenoxy]ethyl]-1-piperidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 314064-32-9 HCAPLUS
CN 4-Thiazolecarboxylic acid, 2-[4-[2-[4-[(ethoxyimino)methyl]phenoxy]ethyl]-1-piperidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 314064-33-0 HCAPLUS

CN Benzaldehyde, 4-[2-[1-(6-chloropyrazinyl)-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314064-34-1 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(2-benzoxazolyl)-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314064-36-3 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314064-40-9 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(5-ethyl-2-pyrimidinyl)-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314064-44-3 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(2-benzothiazolyl)-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314064-46-5 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(2-benzothiazolyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-47-6 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-2-quinoxalinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-48-7 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-5-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-49-8 HCAPLUS
CN Benzaldehyde, 4-[[5-[(6-chloro-3-pyridazinyl)amino]pentyl]oxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-50-1 HCAPLUS
CN Benzaldehyde, 4-[[5-[(6-chloro-3-pyridazinyl)methylamino]pentyl]oxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-51-2 HCAPLUS
CN Benzaldehyde, 4-[[6-[(6-chloro-3-pyridazinyl)amino]hexyl]oxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-52-3 HCAPLUS
CN Benzaldehyde, 4-[4-[(6-chloro-3-pyridazinyl)amino]butoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-53-4 HCAPLUS
CN Benzaldehyde, 4-[[6-[(6-chloro-3-pyridazinyl)methylamino]hexyl]oxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314064-54-5 HCAPLUS
CN Benzaldehyde, 4-[4-[(6-chloro-3-pyridazinyl)methylamino]butoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-55-6 HCAPLUS
CN Benzaldehyde, 4-[[5-[(6-chloro-3-pyridazinyl)oxy]pentyl]oxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-56-7 HCAPLUS
CN Benzaldehyde, 4-[(6-chloro-2-quinoxalinyl)oxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-57-8 HCAPLUS
CN 4-Thiazolecarboxaldehyde, 2-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-58-9 HCAPLUS
CN 4-Thiazolecarboxaldehyde, 2-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



IT **314062-99-2 314063-03-1 314063-14-4**
314063-21-3 314063-24-6 314063-29-1
314063-30-4 314063-31-5 314063-34-8
314063-49-5 314063-50-8 314063-54-2
314063-56-4 314063-58-6 314063-62-2
314063-63-3 314063-65-5 314063-88-2
314063-92-8 314063-93-9 314063-94-0
314063-97-3 314064-00-1 314064-02-3
314064-10-3 314064-11-4 314064-12-5
314064-35-2 314064-38-5 314064-42-1
314255-60-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of (heterocyclyl)alkoxy benzaldehyde oximes as antiviral agents)

RN 314062-99-2 HCAPLUS
CN Benzaldehyde, 4-[[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]methoxy]-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314063-03-1 HCAPLUS
CN 1-Propanone, 1-[4-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]phenyl]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-14-4 HCAPLUS
CN Benzaldehyde, 3-methyl-4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314063-21-3 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-methoxy-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314063-24-6 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314063-29-1 HCAPLUS
CN Benzaldehyde, 4-[3-[1-[6-(trifluoromethyl)-3-pyridazinyl]-4-piperidinyl]propoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-30-4 HCAPLUS
CN Benzaldehyde, 4-[3-[1-(3-pyridazinyl)-4-piperidinyl]propoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-31-5 HCAPLUS
CN Benzaldehyde, 4-[3-[1-(3-pyridazinyl)-4-piperidinyl]propoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-34-8 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-(2-fluoroethyl)oxime (9CI) (CA INDEX NAME)



RN 314063-49-5 HCAPLUS
CN Benzaldehyde, 3-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-5-

hydroxy-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-50-8 HCAPLUS
CN Benzaldehyde, 3-[2-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]ethoxy]-5-hydroxy-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314063-54-2 HCAPLUS
CN Benzaldehyde, 3-[2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-56-4 HCAPLUS
CN Benzaldehyde, 3-[[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]methoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-58-6 HCAPLUS
CN Benzaldehyde, 3-[3-[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]propoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-62-2 HCAPLUS
CN Benzaldehyde, 3-[3-[1-(6-methoxy-3-pyridazinyl)-4-piperidinyl]propoxy]-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314063-63-3 HCAPLUS
CN Benzaldehyde, 3-[3-[1-(3-pyridazinyl)-4-piperidinyl]propoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314063-65-5 HCAPLUS
CN Benzaldehyde, 3-[3-[1-(3-pyridazinyl)-4-piperidinyl]propoxy]-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314063-88-2 HCAPLUS
CN Benzaldehyde, 4-[3-(3-cyclopropyl-5-isoxazolyl)propoxy]-3,5-dimethyl-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-92-8 HCAPLUS
CN Benzaldehyde, 4-[2-[4-(3-pyridazinyl)-1-piperazinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-93-9 HCAPLUS
CN Benzaldehyde, 3-[2-[4-(3-pyridazinyl)-1-piperazinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314063-94-0 HCAPLUS
CN Benzaldehyde, 4-[2-[4-(3-pyridazinyl)-1-piperazinyl]ethoxy]-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314063-97-3 HCAPLUS
CN Benzaldehyde, 4-[2-[4-(6-methyl-3-pyridazinyl)-1-piperazinyl]ethoxy]-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314064-00-1 HCAPLUS
CN Benzaldehyde, 3-[2-[4-(6-methyl-3-pyridazinyl)-1-piperazinyl]ethoxy]-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314064-02-3 HCAPLUS
CN Benzaldehyde, 4-[2-[4-(6-chloro-3-pyridazinyl)-1-piperazinyl]ethoxy]-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314064-10-3 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-3-piperidinyl]ethoxy]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 314064-11-4 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-3-piperidinyl]ethoxy]-, O-2-propenyloxime (9CI) (CA INDEX NAME)



RN 314064-12-5 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(6-chloro-3-pyridazinyl)-3-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-35-2 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(2-benzoxazolyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-38-5 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314064-42-1 HCAPLUS
CN Benzaldehyde, 4-[2-[1-(5-ethyl-2-pyrimidinyl)-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)



RN 314255-60-2 HCAPLUS
CN Benzaldehyde, 4-[2-[1-[6-methyloxido-3-pyridazinyl]-4-piperidinyl]ethoxy]-, O-ethyloxime (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> => d all hitstr tot 187

L87 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:220079 HCAPLUS
DN 140:253575
ED Entered STN: 19 Mar 2004
TI Preparation of heteroaryl-substituted pyrrole derivatives that inhibit production of TNFα
IN Kimura, Tomio; Aoki, Kazumasa; Nakao, Akira; Ushiyama, Shigeru; Shimozato, Takaichi; Ohkawa, Nobuyuki; Nagasaki, Takayoshi; Yamazaki, Takanori

PA Sankyo Company, Limited, Japan
SO U.S. Pat. Appl. Publ., 244 pp., Cont.-in-part of U.S. Ser. No. 317,748, abandoned.
CODEN: USXXCO
DT Patent
LA English
IC ICM C07D417-14
ICS C07D413-14; C07D043-14
NCL 544060000; 544141000; 544295000; 544333000; 546193000; 546269700; 546271400; 546272700; 546276400
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 3

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 2004054173	A1	20040318		US 2003-354648	20030130	<--
	RU 2198170	C2	20030210		RU 2000-119431	20000720	<--
	ZA 2000003705	A	20010205		ZA 2000-3705	20000721	<--
	JP 2002284783	A2	20021003		JP 2002-12247	20020122	
PRAI	JP 1999-205491	A	19990721	<--			
	JP 1999-369678	A	19991227	<--			
	US 2000-619898	B3	20000719				
	JP 2001-13817	A	20010122				
	US 2001-275005P	P	20010312				
	US 2002-54630	B2	20020122				
	US 2002-99176	B1	20020314				
	US 2002-317748	B2	20021212				

GI



I



II

AB Title compds. I [A = pyrrole; R1 = (un)substituted Ph, naphthyl, etc.; R2 = pyridinyl, pyrimidinyl, etc.; R3 = heterocyclyl] are prepared For instance, α-(p-toluenesulfonyloxy)-4-fluorobenzylisonitrile is reacted with 3-(4-pyridyl)acrylate (THF, n-BuLi, LiBr, -45°) to give 4-(ethoxycarbonyl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole. This Et ester is reduced (THF/PhMe, DIBAL), oxidized to the 4-formyl derivative (DMSO, MnO2, 50°), condensed with diethylphosphonoacetonitrile (THF, NaH). This adduct was reduced (THF/MeOH, H2-Pd/C) and reduced (THF, LAH) to give II. Compds. of the

invention inhibit production of TNFα and IL-1β. I are useful for the treatment of inflammation.

ST heteroaryl pyrrole pyridine pyrimidine TNF interleukin inhbitor prepn

IT Intestine, disease
(Crohn's; preparation of heteroaryl-substituted pyrrole derivs. that inhibit production of TNFα)

IT Bone
(absorption, inhibition of; preparation of heteroaryl-substituted pyrrole derivs. that inhibit production of TNFα)

IT Heart, disease
(ischemia; preparation of heteroaryl-substituted pyrrole derivs. that inhibit production of TNFα)

IT Kidney, disease
(nephritis; preparation of heteroaryl-substituted pyrrole derivs. that inhibit production of TNFα)

IT Allergy inhibitors
Alzheimer's disease
Analgesics
Anti-Alzheimer's agents
Anti-inflammatory agents
Antiarteriosclerotics
Antiarthritics
Antidiabetic agents
Antirheumatic agents
Antiviral agents
Arteriosclerosis
Diabetes mellitus
Fever and Hyperthermia
Hepatitis
Human
Lupus erythematosus
Osteoarthritis
Osteoporosis
Pain
Psoriasis
Rheumatoid arthritis
Septicemia
(preparation of heteroaryl-substituted pyrrole derivs. that inhibit production of TNFα)

IT Cytokines
Interleukin 1β
Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of heteroaryl-substituted pyrrole derivs. that inhibit production of TNFα)

IT Intestine, disease
(ulcerative colitis; preparation of heteroaryl-substituted pyrrole derivs. that inhibit production of TNFα)

IT 321344-57-4P 321344-58-5P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryl-substituted pyrrole derivs. that inhibit production of TNFα)

IT 321343-74-2P, 4-(3-Aminopropyl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321343-78-6P, 4-Aminomethyl-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole Dihydrochloride 321343-82-2P, 4-(1-Acetyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321343-83-3P, 2-(4-Fluorophenyl)-3-(pyridin-4-yl)-4-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrole dihydrochloride 321343-86-6P,

1-(1-Benzylpiperidin-4-yl)-3-(4-fluorophenyl)-2-(pyridin-4-yl)-1H-pyrrole 321343-87-7P, 3-(4-Fluorophenyl)-1-(piperidin-4-yl)-2-(pyridin-4-yl)-1H-pyrrole 321343-98-0P 321344-06-3P, 2-(4-Fluorophenyl)-4-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-09-6P 321344-17-6P, 2-(4-Fluorophenyl)-4-(8-methyl-8-azabicyclo[3.2.1]oct-2-en-3-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-19-8P, 4-(8-Azabicyclo[3.2.1]oct-2-en-3-yl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-21-2P, 2-(4-Fluorophenyl)-3-(pyridin-4-yl)-4-(1,2,3,6-tetrahydro-2,2,6,6-tetramethylpyridin-4-yl)-1H-pyrrole 321344-24-5P, 2-(4-Fluorophenyl)-4-(6-methyl-1,2,3,6-tetrahydropyridin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-26-7P 321344-28-9P, 2-(4-Fluorophenyl)-4-(1-isopropyl-1,2,3,6-tetrahydropyridin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-33-6P, 2-(4-Fluorophenyl)-4-(1,2,3,5,8,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-34-7P, 2-(4-Fluorophenyl)-4-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-37-0P, 2-(4-Fluorophenyl)-4-(1,2,2,6,6-pentamethyl-1,2,3,6-tetrahydropyridin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heteroaryl-substituted pyrrole derivs. that inhibit production of TNFα)

IT 321343-75-3P, 2-(4-Fluorophenyl)-3-(pyridin-4-yl)-4-(3-trifluoroacetylaminopropyl)-1H-pyrrole 321343-76-4P, 4-(3-Acetylaminopropyl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321343-77-5P, 2-(4-Fluorophenyl)-4-(3-methylaminopropyl)-3-(pyridin-4-yl)-1H-pyrrole 321343-79-7P, 2-(4-Fluorophenyl)-3-(pyridin-4-yl)-4-(2,4,6-trifluorobenzoylaminomethyl)-1H-pyrrole 321343-80-0P, 2-(4-Fluorophenyl)-3-(pyridin-4-yl)-4-(2,3,5,6-tetrafluoropyridin-4-yl)-1H-pyrrole 321343-81-1P, [5-(4-Fluorophenyl)-4-(pyridin-4-yl)-1H-pyrrol-3-yl](pyridin-4-yl)methanol 321343-84-4P, 2-(4-Fluorophenyl)-4-(piperidin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole 321343-88-8P, 3-(4-Fluorophenyl)-1-(1-methylpiperidin-4-yl)-2-(pyridin-4-yl)-1H-pyrrole 321343-89-9P, 1-(1-Acetylpiperidin-4-yl)-3-(4-fluorophenyl)-2-(pyridin-4-yl)-1H-pyrrole 321343-90-2P, 3-(4-Fluorophenyl)-1-[1-(2-nitroethyl)piperidin-4-yl]-2-(pyridin-4-yl)-1H-pyrrole 321343-92-4P, 3-(4-Fluorophenyl)-2-(pyridin-4-yl)-1-(pyrrolidin-3-yl)-1H-pyrrole 321343-93-5P, 3-(4-Fluorophenyl)-1-(piperidin-3-yl)-2-(pyridin-4-yl)-1H-pyrrole 321343-94-6P, 3-(4-Fluorophenyl)-1-(piperidin-4-yl)methyl-2-(pyridin-4-yl)-1H-pyrrole 321343-95-7P, 1-(Azetidin-3-yl)-3-(4-fluorophenyl)-2-(pyridin-4-yl)-1H-pyrrole dihydrochloride 321343-96-8P, 1-(3-Aminopropyl)-3-(4-fluorophenyl)-2-(pyridin-4-yl)-1H-pyrrole 321343-97-9P, 2-(4-Fluorophenyl)-3-(pyridin-4-yl)-4-[3-(thiomorpholinyl)propyl]-1H-pyrrole 321343-99-1P, 2-(4-Fluorophenyl)-4-[3-(piperazin-1-yl)propyl]-3-(pyridin-4-yl)-1H-pyrrole 321344-00-7P, 4-(3-Dimethylaminopropyl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-01-8P, 2-(4-Fluorophenyl)-4-[3-(morpholinyl)propyl]-3-(pyridin-4-yl)-1H-pyrrole 321344-02-9P, 2-(4-Fluorophenyl)-4-[3-(piperidin-1-yl)propyl]-3-(pyridin-4-yl)-1H-pyrrole 321344-03-0P, 2-(4-Fluorophenyl)-4-[3-(1-methylpiperazin-4-yl)propyl]-3-(pyridin-4-yl)-1H-pyrrole 321344-04-1P, 1-(3-Dimethylaminopropyl)-3-(4-fluorophenyl)-2-(pyridin-4-yl)-1H-pyrrole 321344-05-2P, 2-(4-Fluorophenyl)-3,4-bis(pyridin-4-yl)-1H-pyrrole 321344-07-4P, 2-(4-Fluorophenyl)-4-(1-methylpiperidin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-08-5P, 3-(4-Fluorophenyl)-2-(pyridin-4-yl)-1-(2,2,6,6-tetramethylpiperidin-4-yl)-1H-pyrrole 321344-10-9P, 2-(4-Fluorophenyl)-3-(pyridin-4-yl)-4-(quinuclidin-3-yl)-1H-pyrrole 321344-11-0P, 2-(4-Fluorophenyl)-4-(4-hydroxypiperidin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-12-1P, 2-(4-Fluorophenyl)-4-(3-((methanesulfonyl)amino)propyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-13-2P, 3-(4-Fluorophenyl)-2-(pyridin-4-yl)-1-(quinuclidin-3-yl)-1H-pyrrole 321344-14-3P, 3-(4-Fluorophenyl)-1-(piperidin-3-yl)methyl-2-(pyridin-4-yl)-1H-pyrrole 321344-15-4P, cis-1-(4-Aminocyclohexyl)-3-(4-

fluorophenyl)-2-(pyridin-4-yl)-1H-pyrrole 321344-16-5P, 3-(4-Fluorophenyl)-2-(2-methylaminopyrimidin-4-yl)-1-(piperidin-4-yl)-1H-pyrrole 321344-18-7P, 2-(4-Fluorophenyl)-4-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-20-1P, 4-(8-Azabicyclo[3.2.1]octan-3-yl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-22-3P, 2-(4-Fluorophenyl)-3-(Pyridin-4-yl)-4-(2,2,6,6-tetramethylpiperidin-4-yl)-1H-pyrrole 321344-23-4P, 2-(4-Fluorophenyl)-4-(2-methyl-1,2,3,6-tetrahydropyridin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-25-6P, 2-(4-Fluorophenyl)-4-(2-methylpiperidin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-27-8P, 4-(1-Ethylpiperidin-4-yl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-29-0P, 2-(4-Fluorophenyl)-4-(1-isopropylpiperidin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-30-3P, 2-(4-Fluorophenyl)-4-(1-propyl-1,2,3,6-tetrahydropyridin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-31-4P, 4-(1-Benzyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-32-5P, 2-(4-Fluorophenyl)-4-(1-phenethyl-1,2,3,6-tetrahydropyridin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-35-8P, 4-(1,6-Dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-36-9P, 4-(1,2-Dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-38-1P, 2-(4-Fluorophenyl)-4-(1,2,2,6,6-pentamethylpiperidin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-39-2P, 2-(4-Fluorophenyl)-3-(pyridin-4-yl)-4-(1,2,3,6-tetrahydropyridin-5-yl)-1H-pyrrole 321344-41-6P, 4-(4-Aminobutyl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-42-7P, 1-(2-Dimethylaminoethyl)-3-(4-fluorophenyl)-2-(pyridin-4-yl)-1H-pyrrole 321344-43-8P, 1-(2,2-Dimethyl-3-dimethylaminopropyl)-3-(4-fluorophenyl)-2-(pyridin-4-yl)-1H-pyrrole 321344-44-9P, 1-(8-Azabicyclo[3.2.1]octan-3-yl)-3-(4-fluorophenyl)-2-(pyridin-4-yl)-1H-pyrrole 321344-45-0P, 3-(4-Fluorophenyl)-1-(2-methylpiperidin-4-yl)-2-(pyridin-4-yl)-1H-pyrrole 321344-46-1P, 3-(4-Fluorophenyl)-2-(2-methylaminopyridin-4-yl)-1-(piperidin-4-yl)-1H-pyrrole 321344-47-2P, 2-(4-Fluorophenyl)-3-[2-((1S)-1-phenylethylamino)pyridin-4-yl]-4-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrole 321344-48-3P, 4-(1-tert-Butyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-49-4P, 2-(4-Fluorophenyl)-4-(1-octyl-1,2,3,6-tetrahydropyridin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-50-7P, 4-(1-Ethyl-6-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-51-8P, 4-(1-Ethyl-2-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-52-9P, 2-(4-Fluorophenyl)-4-(1,2,3,5,6,7,8,8a-octahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-53-0P, 4-(6-Allyl-1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-54-1P, 4-(2-Allyl-1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-55-2P, 4-(6-Benzyl-1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-56-3P, 4-(2-Benzyl-1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-59-6P, 2-(4-Fluorophenyl)-4-(6-methyl-1-propyl-1,2,3,6-tetrahydropyridin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-61-0P, 2-(4-Fluorophenyl)-4-(2-methyl-1-propyl-1,2,3,6-tetrahydropyridin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-62-1P, 2-(4-Fluorophenyl)-4-(1,3,4,6,7,9a-hexahydro-2H-quinolizin-8-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-63-2P, 2-(4-Fluorophenyl)-4-(1,3,4,6,9,9a-hexahydro-2H-quinolizin-8-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-64-3P, 2-(4-Fluorophenyl)-4-(1,2,3,5,8,8a-hexahydroindolizin-7-yl)-3-(2-methylaminopyrimidin-4-yl)-1H-pyrrole 321344-65-4P, 2-(4-Fluorophenyl)-4-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(2-methylaminopyrimidin-4-yl)-1H-pyrrole 321344-66-5P, 2-(3,4-Difluorophenyl)-4-(1,2,3,5,8,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-67-6P, 2-(3,4-Difluorophenyl)-4-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-68-7P, 4-(1,2,3,5,8,8a-Hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-2-(3-trifluoromethylphenyl)-1H-pyrrole 321344-69-8P, 4-(1,2,3,5,6,8a-Hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-2-(3-trifluoromethylphenyl)-1H-

pyrrole 321344-70-1P, 2-(3-Fluorophenyl)-4-(1,2,3,5,8,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-71-2P, 2-(3-Fluorophenyl)-4-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-72-3P, 2-(3-Chlorophenyl)-4-(1,2,3,5,8,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-73-4P, 2-(3-Chlorophenyl)-4-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 321344-74-5P, 4-(1,2,3,5,8,8a-Hexahydroindolizin-7-yl)-2-phenyl-3-(pyridin-4-yl)-1H-pyrrole 321344-75-6P, 4-(1,2,3,5,6,8a-Hexahydroindolizin-7-yl)-2-phenyl-3-(pyridin-4-yl)-1H-pyrrole 321344-76-7P, 2-(4-Fluorophenyl)-3-(pyridin-4-yl)-4-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrole 443912-03-6P 443912-04-7P, 4-(3-Dimethylamino-1-propen-1-yl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 443982-89-6P 443982-91-0P 443982-92-1P 443982-94-3P 443982-95-4P 443982-97-6P 443983-00-4P 443983-02-6P, 2-(4-Fluorophenyl)-3-(pyridin-4-yl)-4-(6,9,9a,10-tetrahydropyrido[1,2-a]indol-8-yl)-1H-pyrrole 443983-04-8P 443983-07-1P 443983-09-3P 443983-13-9P 443983-15-1P 443983-17-3P 443983-19-5P 443983-21-9P 443983-22-0P 443983-26-4P 443983-29-7P 443983-30-0P 443983-32-2P 443983-33-3P 443983-34-4P, 4-(2,2-Diphenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 443983-35-5P 443983-37-7P 443983-39-9P 443983-40-2P 443983-41-3P 443983-43-5P 443983-44-6P 443983-46-8P 443983-48-0P 443983-49-1P 443983-51-5P 443983-52-6P 443983-54-8P 443983-58-2P 443983-61-7P 443983-64-0P 443983-65-1P 443983-67-3P 443983-68-4P 443983-69-5P 443983-70-8P 443983-72-0P 443983-75-3P 443983-78-6P 443983-80-0P 443983-82-2P 443983-84-4P 443984-43-8P, 2-(3-Fluorophenyl)-4-(2-methyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 443984-44-9P, 2-(3-Fluorophenyl)-4-(2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 443984-45-0P, 2-(3-Fluorophenyl)-4-(2-methoxy-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 443984-46-1P, 2-(4-Fluorophenyl)-4-(2-methyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 443984-47-2P, 2-(4-Fluorophenyl)-4-(2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 443984-48-3P, 2-(4-Fluorophenyl)-4-(2-methoxy-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 443984-49-4P, 2-(3-Chlorophenyl)-4-(2-methyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 443984-50-7P, 2-(3-Chlorophenyl)-4-(2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 443984-51-8P, 4-(2-Methyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-2-(3-trifluoromethylphenyl)-1H-pyrrole 443984-52-9P, 4-(2-Phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-2-(3-trifluoromethylphenyl)-1H-pyrrole 443984-53-0P, 4-(2-Methoxy-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-2-(3-trifluoromethylphenyl)-1H-pyrrole 443984-54-1P, 2-(4-Fluorophenyl)-4-(2-methyl-3,5,6,8a-tetrahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 443984-55-2P, 2-(4-Fluorophenyl)-4-(2-methylidene-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 443984-56-3P, 4-(2-Ethyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 443984-57-4P, 4-(2-Ethyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-2-(3-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 443984-58-5P, 2-(3-Chlorophenyl)-4-(2-ethyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 443984-59-6P, 4-(2-Ethyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-2-(3-trifluoromethylphenyl)-1H-pyrrole 443984-60-9P, 2-(4-Fluorophenyl)-4-(2-propyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 443984-61-0P, 2-(3-Fluorophenyl)-4-(2-propyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 443984-62-1P, 2-(3-Chlorophenyl)-4-(2-propyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 443984-63-2P, 4-(2-Propyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-2-(3-trifluoromethylphenyl)-1H-pyrrole 443984-64-3P, 4-(2-Ethyl-3,5,6,8a-tetrahydroindolizin-7-yl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 443984-65-4P, 2-(4-Fluorophenyl)-4-(2-propyl-3,5,6,8a-tetrahydroindolizin-

7-yl)-3-(pyridin-4-yl)-1H-pyrrole 443984-66-5P, 2-(4-Fluorophenyl)-4-(2-phenyl-3,5,6,8a-tetrahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole 443984-68-7P, 2-(4-Fluorophenyl)-3-(Pyridin-4-yl)-4-(6,7,9a,10-tetrahydropyrido[1,2-a]indol-8-yl)-1H-pyrrole 471864-21-8P 476487-12-4P 476487-13-5P 670274-00-7P, 4-(1,2,3,5,6,8a-Hexahydroindolizin-7-yl)-2-phenyl-3-(pyrazin-4-yl)-1H-pyrrole 670274-08-5P, 2-(3-Chlorophenyl)-4-(2-methoxy-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(pyridin-4-yl)-1H-pyrrole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryl-substituted pyrrole derivs. that inhibit production of TNFα)

IT 78-94-4, Methyl vinyl ketone, reactions 105-36-2, Ethyl bromoacetate 108-00-9, 2-Dimethylaminoethylamine 109-01-3, 1-Methylpiperazine 109-55-7, 3-Dimethylaminopropylamine 109-65-9, Butyl bromide 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 123-00-2, 4-(3-Aminopropyl)morpholine 123-75-1, Pyrrolidine, reactions 123-90-0, Thiomorpholine 501-53-1, Benzyl chloroformate 532-24-1, 8-Methyl-8-azabicyclo[3.2.1]octan-3-one 700-16-3, Pentafluoropyridine 826-36-8, 2,2,6,6-Tetramethylpiperidin-4-one 867-13-0, Ethyl diethylphosphonoacetate 872-85-5, 4-Formylpyridine 1074-68-6, 4-Formyl-2-methylthiopyrimidine 1445-73-4, 1-Methylpiperidin-4-one 1449-46-3, Benzyltriphenylphosphonium bromide 1465-76-5, 1-tert-Butylpiperidin-4-one 2032-35-1, Bromoacetaldehyde diethyl acetal 2407-99-0, 1,2,3,5,6,7,8,8a-Octahydroindolizin-7-one 2537-48-6, Diethylphosphonoacetonitrile 2627-86-3, (S)-1-Phenylethylamine 2759-28-6, 1-Benzylpiperazine 3612-18-8, 1-Ethylpiperidin-4-one 3612-20-2, 1-Benzylpiperidin-4-one 3731-38-2, Quinuclidin-3-one 4124-41-8, p-Toluenesulfonic anhydride 4254-02-8, Cyclopentanecarbonitrile 5355-68-0, 1-Isopropylpiperidin-4-one 5554-54-1, 1,2,2,6,6-Pentamethylpiperidin-4-one 6238-14-8, 3-Aminoquinuclidine 13669-32-4, 1,2-Dimethylpiperidin-4-one 16217-15-5, (S)-1-Benzyloxycarbonyl-4-oxoproline methyl ester 16217-17-7 16728-64-6, 3-Benzyloxypropylamine 18942-89-7, 2-Nitroethyl acetate 21823-56-3, 2-Benzyl-1-methylpiperidin-4-one 23133-37-1, 1-Propylpiperidin-4-one 23581-42-2, Octahydro-2H-quinolizin-2-one 24489-96-1, Ethyl 3-(4-pyridyl)acrylate 24654-55-5, 3-(4-Fluorophenyl)acrolein 28957-72-4, 8-Benzyl-8-azabicyclo[3.2.1]octan-3-one 33329-70-3, 1-Ethoxycarbonyl-1-formylcyclopropane 36635-66-2 36768-62-4, 4-Amino-2,2,6,6-tetramethylpiperidine 37517-81-0, Methyl malonyl chloride 39742-60-4, 1-Phenethylpiperidin-4-one 40114-49-6, 1-Benzylpiperidin-3-one 40432-52-8, 3-Amino-1-(diphenylmethyl)azetidine 50541-93-0, 4-Amino-1-benzylpiperidine 53369-71-4, 2,2-Dimethyl-3-dimethylaminopropylamine 64187-48-0, (2S,4R)-1-Benzyloxycarbonyl-4-hydroxypyrrolidin-2-carboxylic acid methyl ester 71072-32-7, 1-Octylpiperidin-4-one 72180-27-9, (2S)-1-Benzyloxycarbonyl-4,4-difluoroproline 75776-70-4 79538-29-7, 2,4,6-Trifluorobenzoyl chloride 96522-37-1, (2S,4R)-1-Benzyloxycarbonyl-4-methoxypyrrolidin-2-carboxylic acid 96901-92-7, 3-Amino-8-benzyl-8-azabicyclo[3.2.1]octane 113490-82-7 115031-85-1, 2,2-Diphenyl-1,2,3,5,6,7,8,8a-octahydroindolizin-7-one 131747-69-8, 2-Fluoropyridine-4-carboxaldehyde 135829-03-7, Methyl 1-benzyloxycarbonylindoline-2-carboxylate 144222-22-0, 4-Aminomethyl-1-(tert-butoxycarbonyl)piperidine 153290-87-0, (2S,4R)-1-Benzyloxycarbonyl-4-ethoxypyrrolidin-2-carboxylic acid 156088-46-9, (S)-4,4-Dimethyl-2-hydroxymethyl-5-oxopyrrolidine 162167-97-7, 3-Aminomethyl-1-(tert-butoxycarbonyl)piperidine 165806-95-1, α-(p-Toluenesulfonyl)-4-fluorobenzylisonitrile 184637-48-7, 3-Amino-1-(tert-butoxycarbonyl)piperidine 185212-91-3 186550-13-0, 3-Amino-1-(tert-butoxycarbonyl)pyrrolidine 190906-83-3, 2-Methyl-1-propylpiperidin-4-one 203661-73-8, 1-Benzyl-2-methylpiperidin-4-one 247570-24-7, cis-4-((tert-Butoxycarbonyl)amino)cyclohexane-1-amine

263389-45-3 288620-86-0, (2S,4R)-1-Benzyloxycarbonyl-4-hydroxypiperidin-2-carboxylic acid benzyl ester 306296-67-3, 1-Allyloxycarbonylpiperidin-4-one **321344-85-8** 321345-30-6, 4-Amino-1-benzyl-2-methylpiperidine 321345-31-7, Ethyl 3-(2-fluoropyridin-4-yl)acrylate 321345-32-8, 1-Ethyl-2-methylpiperidin-4-one 321345-33-9, 2-Allyl-1-methylpiperidin-4-one 321345-34-0, Ethyl 3-(2-methylthiopyrimidin-4-yl)acrylate 321345-35-1 321345-36-2 321345-37-3 443983-92-4, 2-(3-Ethoxycarbonyl-2-oxopropyl)indoline 443983-94-6, Methyl (S)-1-benzyloxycarbonyl-4-phenyl-3-pyrroline-2-carboxylate 443984-09-6, (2S,4S)-4-Methoxypiperidin-2-carboxylic acid hydrochloride 443984-25-6, (S)-1-(Benzyloxycarbonyl)piperidin-2-carboxylic acid ethyl ester 443984-41-6 443984-42-7 670274-03-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heteroaryl-substituted pyrrole derivs. that inhibit production of TNFα)

IT 16217-18-8P 135829-04-8P, 1-Benzyloxycarbonylindoline-2-methanol 165807-04-5P 200184-60-7P, (S)-1-Benzyloxycarbonyl-4-methylideneproline Methyl Ester 290357-27-6P, 2-(4-Fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-79-0P, 4-Ethoxycarbonyl-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-80-3P, 2-(4-Fluorophenyl)-4-hydroxymethyl-3-(pyridin-4-yl)-1H-pyrrole 321344-81-4P, 2-(4-Fluorophenyl)-4-formyl-3-(pyridin-4-yl)-1H-pyrrole 321344-83-6P, 4-(2-Cyanoethyl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-84-7P, 4-[3-(tert-Butoxycarbonylamino)propyl]-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321344-86-9P, 2-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(triisopropylsilyl)-1H-pyrrole 321344-87-0P, 4-Bromo-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1-triisopropylsilyl-1H-pyrrole 321344-88-1P, [5-(4-Fluorophenyl)-4-(pyridin-4-yl)-1-triisopropylsilyl-1H-pyrrol-3-yl](pyridin-4-yl)methanol 321344-89-2P 321344-90-5P, 2-(4-Fluorophenyl)-4-(4-hydroxypiperidin-4-yl)-3-(pyridin-4-yl)-1-triisopropylsilyl-1H-pyrrole 321344-92-7P 321344-93-8P, 1-[1-(tert-Butoxycarbonyl)pyrrolidin-3-yl]-3-(4-fluorophenyl)-2-(pyridin-4-yl)-1H-pyrrole 321344-94-9P, 1-(1-(Diphenylmethyl)azetidin-3-yl)-3-(4-fluorophenyl)-2-(pyridin-4-yl)-1H-pyrrole 321344-95-0P, 1-(3-Benzyloxypropyl)-3-(4-fluorophenyl)-2-(pyridin-4-yl)-1H-pyrrole 321344-96-1P, 3-(4-Fluorophenyl)-1-(3-hydroxypropyl)-2-(pyridin-4-yl)-1H-pyrrole 321344-97-2P, 3-(4-Fluorophenyl)-2-(pyridin-4-yl)-1-[3-(4-toluenesulfonyloxy)propyl]-1H-pyrrole 321344-98-3P, 1-(3-Azidopropyl)-3-(4-fluorophenyl)-2-(pyridin-4-yl)-1H-pyrrole 321345-00-0P, 4-(2-Ethoxycarbonylethyl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321345-01-1P, 2-(4-Fluorophenyl)-4-(3-hydroxypropyl)-3-(pyridin-4-yl)-1H-pyrrole 321345-02-2P, 2-(4-Fluorophenyl)-3-(pyridin-4-yl)-4-[3-(4-toluenesulfonyloxy)propyl]-1H-pyrrole 321345-03-3P, 2-(4-Fluorophenyl)-4-(4-hydroxy-1-methylpiperidin-4-yl)-3-(pyridin-4-yl)-1-triisopropylsilyl-1H-pyrrole 321345-04-4P 321345-05-5P, 1-(1-Benzylpiperidin-4-yl)-3-(4-fluorophenyl)-2-(2-methylthiopyrimidin-4-yl)-1H-pyrrole 321345-06-6P, 1-(1-Benzylpiperidin-4-yl)-3-(4-fluorophenyl)-2-(2-(methanesulfonyl)pyrimidin-4-yl)-1H-pyrrole 321345-07-7P, 1-(1-Benzylpiperidin-4-yl)-3-(4-fluorophenyl)-2-(2-methylaminopyrimidin-4-yl)-1H-pyrrole 321345-11-3P, 4-(3-Cyanopropyl)-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrole 321345-12-4P, 1-(1-Benzylpiperidin-4-yl)-3-(4-fluorophenyl)-2-(2-fluoropyridin-4-yl)-1H-pyrrole 321345-13-5P, 1-(1-Benzylpiperidin-4-yl)-3-(4-fluorophenyl)-2-(2-methylaminopyridin-4-yl)-1H-pyrrole 321345-14-6P, 4-Bromo-2-(4-fluorophenyl)-3-(2-fluoropyridin-4-yl)-1-triisopropylsilyl-1H-pyrrole 321345-15-7P 321345-16-8P, 4-(1-Allyloxycarbonyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4-fluorophenyl)-3-[2-((1S)-phenylethylamino)pyridin-4-yl]-1H-pyrrole 321345-17-9P, 4-Bromo-2-(4-fluorophenyl)-3-(2-methylaminopyrimidin-4-yl)-1-triisopropylsilyl-1H-pyrrole 321345-18-0P, 2-(4-Fluorophenyl)-3-(2-methylthiopyrimidin-4-yl)-1H-pyrrole 321345-19-1P, 2-(4-Fluorophenyl)-3-(2-(methanesulfonyl)pyrimidin-4-yl)-1H-pyrrole 321345-20-4P, 2-(4-Fluorophenyl)-3-(2-methylaminopyrimidin-4-yl)-1H-pyrrole

321345-21-5P, 2-(4-Fluorophenyl)-3-(2-methylaminopyrimidin-4-yl)-1-triisopropylsilyl-1H-pyrrole 321345-22-6P, 3-[2-[N-(tert-Butoxycarbonyl)-N-methylamino]pyrimidin-4-yl]-2-(4-fluorophenyl)-1-triisopropylsilyl-1H-pyrrole 321345-23-7P, 4-Bromo-3-[2-(N-tert-butoxycarbonyl-N-methylamino)pyrimidin-4-yl]-2-(4-fluorophenyl)-1-triisopropylsilyl-1H-pyrrole 321345-24-8P, 4-Bromo-2-(4-fluorophenyl)-3-(2-methylaminopyrimidin-4-yl)-1H-pyrrole 321345-25-9P, 4-Bromo-2-phenyl-3-(pyridin-4-yl)-1-triisopropylsilyl-1H-pyrrole 321345-26-0P, 4-Bromo-2-(3-chlorophenyl)-3-(pyridin-4-yl)-1-triisopropylsilyl-1H-pyrrole 321345-27-1P, 4-Bromo-2-(3-fluorophenyl)-3-(pyridin-4-yl)-1-triisopropylsilyl-1H-pyrrole 321345-28-2P 321345-29-3P, 4-Bromo-3-(pyridin-4-yl)-2-(3-trifluoromethylphenyl)-1-triisopropylsilyl-1H-pyrrole 335650-15-2P, (2S,4R)-1-Benzyloxycarbonyl-4-methoxy-2-hydroxymethylpyrrolidine 443685-77-6P 443912-06-9P, 3-[2-(4-Fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrol-4-yl]acrylonitrile 443912-07-0P, Ethyl 3-[2-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrrol-4-yl]acrylate 443912-08-1P, 2-(4-Fluorophenyl)-4-(3-hydroxy-1-propen-1-yl)-3-(pyridin-4-yl)-1H-pyrrole 443912-09-2P 443982-90-9P, (2R,8AS)-2-methoxy-1,2,3,5,6,7,8,8a-octahydroindolizin-7-one 443982-93-2P 443982-96-5P, (2S,8AS)-2-chloro-1,2,3,5,6,7,8,8a-octahydroindolizin-7-one 443982-99-8P, (8AS)-2,2-difluoro-1,2,3,5,6,7,8,8a-octahydroindolizin-7-one 443983-03-7P, 6,7,8,9,9a,10-Hexahydropyrido[1,2-a]indol-8-one 443983-05-9P, (2R,8AS)-2-phenyl-1,2,3,5,6,7,8,8a-octahydroindolizin-7-one 443983-11-7P 443983-16-2P 443983-20-8P 443983-24-2P 443983-28-6P, (2S,8AS)-2-methoxy-1,2,3,5,6,7,8,8a-octahydroindolizin-7-one 443983-31-1P, (8AS)-2-methylidene-1,2,3,5,6,7,8,8a-octahydroindolizin-7-one 443983-36-6P, (8AS)-2,2-dimethyl-1,2,3,5,6,7,8,8a-octahydroindolizin-7-one 443983-42-4P, (8AS)-2-methyl-3,5,6,7,8,8a-hexahydroindolizin-7-one 443983-45-7P, (2S,8AS)-2-ethyl-1,2,3,5,6,7,8,8a-octahydroindolizin-7-one 443983-47-9P, (2S,8AS)-2-butylthio-1,2,3,5,6,7,8,8a-octahydroindolizin-7-one 443983-50-4P 443983-53-7P 443983-55-9P 443983-63-9P, (2S,8AS)-2-propyl-1,2,3,5,6,7,8,8a-octahydroindolizin-7-one 443983-66-2P, (2R,8AS)-2-ethoxy-1,2,3,5,6,7,8,8a-octahydroindolizin-7-one 443983-71-9P, (2S,8AS)-2-benzyl-1,2,3,5,6,7,8,8a-octahydroindolizin-7-one 443983-74-2P 443983-77-5P, (2S,8AS)-2-phenoxy-1,2,3,5,6,7,8,8a-octahydroindolizin-7-one 443983-85-5P 443983-86-6P, (2S,4R)-1-Benzyloxycarbonyl-2-cyanomethyl-4-methoxypyrrolidine 443983-88-8P, (2S,4R)-1-Benzyloxycarbonyl-2-(3-ethoxycarbonyl-2-oxopropyl)-4-methoxypyrrolidine 443983-89-9P, (2R,8AS)-2-Hydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-7-one 443983-90-2P, 1-Benzyloxycarbonyl-2-cyanomethylindoline 443983-91-3P, 1-Benzyloxycarbonyl-2-(3-ethoxycarbonyl-2-oxopropyl)indoline 443983-93-5P, (S)-1-Benzyloxycarbonyl-2-hydroxymethyl-4-phenyl-3-pyrroline 443983-95-7P, (S)-1-Benzyloxycarbonyl-2-cyanomethyl-4-phenyl-3-pyrroline 443983-96-8P, (2S,4R)-1-Benzyloxycarbonyl-2-cyanomethyl-4-phenylpyrrolidine 443983-97-9P, (2S,4R)-1-Benzyloxycarbonyl-2-(3-(ethoxycarbonyl)-2-oxopropyl)-4-phenylpyrrolidine 443983-98-0P 443983-99-1P 443984-01-8P 443984-02-9P 443984-05-2P 443984-06-3P 443984-07-4P 443984-10-9P 443984-11-0P, (2S,8AS)-2-Methoxy-1,2,3,5,6,7,8,8a-octahydroindolizine-5,7-dione 443984-12-1P, (2S,8AS)-2-Methoxy-7-(1-pyrrolidinyl)-1,2,3,5,8,8a-hexahydroindolizin-5-one 443984-13-2P, (S)-1-Benzyloxycarbonyl-2-cyanomethyl-4-methylidenepyrrolidine 443984-14-3P, (S)-1-(tert-Butoxycarbonyl)-4-methylidenepiperidin-2-carboxylic acid ethyl ester 443984-16-5P, (2S,8AS)-2-methylthio-1,2,3,5,6,7,8,8a-octahydroindolizin-7-one 443984-17-6P, (2S,4S)-1-Benzyloxycarbonyl-2-(tert-butyldimethylsilyloxy)methyl-4-acetylthiopyrrolidine 443984-19-8P 443984-20-1P, (2S,4S)-1-Benzyloxycarbonyl-2-hydroxymethyl-4-methylthiopyrrolidine 443984-21-2P, (2S,4S)-1-Benzyloxycarbonyl-2-cyanomethyl-4-methylthiopyrrolidine 443984-22-3P, (2S,4S)-4-(Methylthio)piperidin-2-carboxylic acid Hydrochloride 443984-23-4P, (2S,8AS)-2-methylsulfonyl-1,2,3,5,6,7,8,8a-octahydroindolizin-7-one 443984-28-9P, (S)-1-Benzyloxycarbonyl-4,4-

dimethyl-2-hydroxymethylpyrrolidine 443984-29-0P 443984-30-3P 443984-31-4P 443984-35-8P 443984-37-0P, (2S,4S)-1-Benzyloxycarbonyl-4-phenoxypiperidin-2-carboxylic acid benzyl ester 443984-40-5P, (2S,4S)-4-Phenoxypiperidin-2-carboxylic acid Hydrochloride 465539-64-4P, 2-(4-Fluorophenyl)-4-(3-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-3-(pyridin-4-yl)-1-triisopropylsilyl-1H-pyrrole 471864-36-5P, (2S,4R)-1-Benzyloxycarbonyl-4-methoxy-2-((methanesulfonyloxy)methyl)pyrrolidine 471864-42-3P, (2S,4R)-1-Benzyloxycarbonyl-2-(tert-butyldimethylsilyloxy)methyl-4-(p-toluenesulfonyloxy)pyrrolidine 476487-17-9P, (S)-4-Methylidenepiperidin-2-carboxylic acid Trifluoroacetate 651736-90-2P 670274-01-8P, 2-(3-Ethoxycarbonyl-2-oxononyl)indoline 670274-02-9P 670274-04-1P, (2S,4S)-4-Methoxy-1-(2-ethoxy-1,2-dioxoethyl)piperidin-2-carboxylic acid 670274-05-2P, (2S,4R)-1-Benzyloxycarbonyl-2-hydroxymethyl-4-(p-toluenesulfonyloxy)pyrrolidine 670274-06-3P, (2S,4R)-1-Benzyloxycarbonyl-4-(p-toluenesulfonyloxy)pyrrolidin-2-carboxylic acid methyl ester 670274-07-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heteroaryl-substituted pyrrole derivs. that inhibit production of TNFα)

IT **321344-85-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heteroaryl-substituted pyrrole derivs. that inhibit production of TNFα)

RN 321344-85-8 HCAPLUS
CN 1H-Pyrrole-3-carboxaldehyde, 5-(4-fluorophenyl)-4-(4-pyridinyl)-, O-methyloxime (9CI) (CA INDEX NAME)



L87 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:62383 HCAPLUS
DN 134:115858
ED Entered STN: 26 Jan 2001
TI Preparation of heteroaryl-substituted pyrroles having excellent inhibitory activity against the production of inflammatory cytokines
IN Kimura, Tomio; Aoki, Kazumasa; Nakao, Akira; Ushiyama, Shigeru; Shimozato, Takaichi; Ohkawa, Nobuyuki
PA Sankyo Company Limited, Japan
SO Eur. Pat. Appl., 367 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM C07D401-04
ICS C07D401-14; C07D453-02; C07D451-02; C07D471-04; C07D455-02; A61P011-06; A61P009-10; A61P017-06; A61P029-00; A61K031-4427; A61K031-4375
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 63

FAN.CNT 3

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	EP 1070711	A2	20010124		EP 2000-306196	20000720	<--
	EP 1070711	A3	20010131				
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO						
	NO 2000003734	A	20010122		NO 2000-3734	20000720	<--
	EP 1243589	A1	20020925		EP 2002-11912	20000720	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY						
	RU 2198170	C2	20030210		RU 2000-119431	20000720	<--
	AU 2000048755	A5	20010201		AU 2000-48755	20000721	<--
	ZA 2000003705	A	20010205		ZA 2000-3705	20000721	<--
	BR 2000004534	A	20010228		BR 2000-4534	20000721	<--
	CN 1295069	A	20010516		CN 2000-131303	20000721	<--
	JP 2001247564	A2	20010911		JP 2000-220199	20000721	<--
PRAI	JP 1999-205491	A	19990721	<--			
	JP 1999-369678	A	19991227	<--			
	EP 2000-306196	A3	20000720				

OS MARPAT 134:115858

GI



I II

AB The title compds. [I; A = pyrrole; R1 = (un)substituted aryl or heteroaryl; R2 = (un)substituted nitrogen-containing heteroaryl; R3 = XR4 (wherein X = a single bond, (un)substituted alkylene, alkenylene, alkynylene; R4 = substituted cycloalkyl, aryl, heterocyclyl, etc.); provided that said substituents R1 and R3 are bonded to the two atoms of said pyrrole ring which are adjacent to the atom of the pyrrole ring to which said substituent R2 is bonded] which have excellent inhibitory activity against the production of inflammatory cytokines such as TNFα (biol. data given) and IL-1β, and are useful in treating arthritis, were prepared and formulated. E.g., a multi-step synthesis of the pyrrole II was given.

ST pyrrole heteroaryl prepn formulation inflammatory cytokine prodn inhibition; tumor necrosis factor alpha prodn inhibition pyrrole heteroaryl prepn; TNF alpha prodn inhibition pyrrole heteroaryl prepn; interleukin 1beta prodn inhibition pyrrole heteroaryl prepn; antiarthritic pyrrole heteroaryl prepn formulation

IT Antiarthritics
(preparation of heteroaryl-substituted pyrroles having excellent inhibitory activity against the production of inflammatory cytokines)

IT Interleukin 1β
Tumor necrosis factors
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(preparation of heteroaryl-substituted pyrroles having excellent inhibitory

activity against the production of inflammatory cytokines)

IT 321343-74-2P 321343-78-6P 321343-82-2P 321343-83-3P 321343-86-6P
321343-87-7P 321343-98-0P 321344-06-3P 321344-09-6P 321344-17-6P
321344-19-8P 321344-24-5P 321344-26-7P 321344-28-9P 321344-33-6P
321344-37-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heteroaryl-substituted pyrroles having excellent inhibitory activity against the production of inflammatory cytokines)

IT 321343-75-3P 321343-76-4P 321343-77-5P 321343-79-7P 321343-80-0P
321343-81-1P 321343-84-4P 321343-88-8P 321343-89-9P 321343-90-2P
321343-91-3P 321343-92-4P 321343-93-5P 321343-94-6P 321343-95-7P
321343-96-8P 321343-97-9P 321343-99-1P 321344-00-7P 321344-01-8P
321344-02-9P 321344-03-0P 321344-04-1P 321344-05-2P 321344-07-4P
321344-08-5P 321344-10-9P 321344-11-0P 321344-12-1P 321344-13-2P
321344-14-3P 321344-15-4P 321344-16-5P 321344-18-7P 321344-20-1P
321344-21-2P 321344-22-3P 321344-23-4P 321344-25-6P 321344-27-8P
321344-29-0P 321344-30-3P 321344-31-4P 321344-32-5P 321344-34-7P
321344-35-8P 321344-36-9P 321344-38-1P 321344-39-2P 321344-40-5P
321344-41-6P 321344-42-7P 321344-43-8P 321344-44-9P 321344-45-0P
321344-46-1P 321344-47-2P 321344-48-3P 321344-49-4P 321344-50-7P
321344-51-8P 321344-52-9P 321344-53-0P 321344-54-1P 321344-55-2P
321344-56-3P 321344-57-4P 321344-58-5P 321344-59-6P 321344-61-0P
321344-62-1P 321344-63-2P 321344-64-3P 321344-65-4P 321344-66-5P
321344-67-6P 321344-68-7P 321344-69-8P 321344-70-1P 321344-71-2P
321344-72-3P 321344-73-4P 321344-74-5P 321344-75-6P 321344-76-7P
321344-77-8P 321344-78-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryl-substituted pyrroles having excellent inhibitory activity against the production of inflammatory cytokines)

IT 108-00-9, 2-Dimethylaminoethylamine 109-01-3, 1-Methylpiperazine
109-55-7, 3-Dimethylaminopropylamine 110-89-4, Piperidine, reactions
110-91-8, Morpholine, reactions 123-00-2, 4-Morpholinepropanamine
123-90-0, Thiomorpholine 532-24-1, 8-Methyl-8-azabicyclo[3.2.1]octan-3-one 700-16-3, Pentafluoropyridine 826-36-8, 2,2,6,6-Tetramethylpiperidin-4-one 867-13-0, Ethyl diethylphosphonoacetate
872-85-5, 4-Formylpyridine 1074-68-6, 4-Formyl-2-methylthiopyrimidine
1445-73-4, 1-Methylpiperidin-4-one 1465-76-5, 1-tert-Butylpiperidin-4-one 2407-99-0 2627-86-3, (S)-1-Phenylethylamine 2759-28-6,
1-Benzylpiperazine 3612-18-8, 1-Ethylpiperidin-4-one 3612-20-2,
1-Benzylpiperidin-4-one 3731-38-2, Quinuclidin-3-one 5355-68-0,
1-Isopropylpiperidin-4-one 5554-54-1, 1,2,2,6,6-Pentamethylpiperidin-4-one 6238-14-8, 3-Aminoquinuclidine 13669-32-4, 1,2-Dimethylpiperidin-4-one 16728-64-6, 3-Benzyloxypropylamine 18942-89-7, 2-Nitroethyl acetate 21823-56-3, 2-Benzyl-1-methylpiperidin-4-one 23133-37-1,
1-Propylpiperidin-4-one 23581-42-2 24489-96-1, Ethyl
3-(4-pyridyl)acrylate 24654-55-5, 3-(4-Fluorophenyl)acrolein
28957-72-4, 8-Benzyl-8-azabicyclo[3.2.1]octan-3-one 36635-66-2
36768-62-4, 4-Amino-2,2,6,6-tetramethylpiperidine 39742-60-4,
1-Phenethylpiperidin-4-one 40114-49-6, 1-Benzylpiperidin-3-one
40432-52-8 50541-93-0, 4-Amino-1-benzylpiperidine 53369-71-4
71072-32-7, 1-Octylpiperidin-4-one 79538-29-7, 2,4,6-Trifluorobenzoyl chloride 96901-92-7, 3-Amino-8-benzyl-8-azabicyclo[3.2.1]octane
131747-69-8, 2-Fluoropyridin-4-carboxaldehyde 144222-22-0,
4-Aminomethyl-1-(tert-butoxycarbonyl)piperidine 162167-97-7
165806-95-1 184637-48-7, 3-Amino-1-(tert-butoxycarbonyl)piperidine
186550-13-0, 3-Amino-1-(tert-butoxycarbonyl)pyrrolidine 190906-83-3,
2-Methyl-1-propylpiperidin-4-one 203661-73-8, 1-Benzyl-2-methylpiperidin-4-one 247570-24-7 263389-45-3 306296-67-3, 1-

Allyloxycarbonylpiperidin-4-one 321345-30-6, 4-Amino-1-benzyl-2-methylpiperidine 321345-31-7, Ethyl 3-(2-fluoropyridin-4-yl)acrylate 321345-32-8, 1-Ethyl-2-methylpiperidin-4-one 321345-33-9, 2-Allyl-1-methylpiperidin-4-one 321345-34-0, Ethyl 3-(2-methylthiopyrimidin-4-yl)acrylate 321345-35-1 321345-36-2 321345-37-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heteroaryl-substituted pyrroles having excellent inhibitory activity against the production of inflammatory cytokines)

IT 165807-04-5P 290357-27-6P 321344-79-0P 321344-80-3P 321344-81-4P
321344-82-5P 321344-83-6P 321344-84-7P **321344-85-8P**
321344-86-9P 321344-87-0P 321344-88-1P 321344-89-2P 321344-90-5P
321344-91-6P 321344-92-7P 321344-93-8P 321344-94-9P 321344-95-0P
321344-96-1P 321344-97-2P 321344-98-3P 321344-99-4P 321345-00-0P
321345-01-1P 321345-02-2P 321345-03-3P 321345-04-4P 321345-05-5P
321345-06-6P 321345-07-7P 321345-08-8P 321345-09-9P 321345-10-2P
321345-11-3P 321345-12-4P 321345-13-5P 321345-14-6P 321345-15-7P
321345-16-8P 321345-17-9P 321345-18-0P 321345-19-1P 321345-20-4P
321345-21-5P 321345-22-6P 321345-23-7P 321345-24-8P 321345-25-9P
321345-26-0P 321345-27-1P 321345-28-2P 321345-29-3P 321422-08-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heteroaryl-substituted pyrroles having excellent inhibitory activity against the production of inflammatory cytokines)

IT **321344-85-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heteroaryl-substituted pyrroles having excellent inhibitory activity against the production of inflammatory cytokines)

RN 321344-85-8 HCAPLUS
CN 1H-Pyrrole-3-carboxaldehyde, 5-(4-fluorophenyl)-4-(4-pyridinyl)-, O-methyloxime (9CI) (CA INDEX NAME)



L87 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:473973 HCAPLUS
DN 129:108993
ED Entered STN: 30 Jul 1998
TI Preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression.
IN Kawai, Akiyoshi; Kawai, Makoto
PA Pfizer Inc., USA
SO Eur. Pat. Appl., 53 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM C07D409-04
ICS C07D405-04; C07D493-04; C07D409-14; C07D495-04; A61K031-44
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	EP 853083	A1	19980715		EP 1997-310375	19971219	<--
	EP 853083	B1	20010912				
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO						
	PT 853083	T	20011228		PT 1997-97310375	19970106	<--
	AT 205494	E	20010915		AT 1997-310375	19971219	<--
	ES 2161418	T3	20011201		ES 1997-310375	19971219	<--
	JP 10195070	A2	19980728		JP 1997-366682	19971226	<--
	JP 3384962	B2	20030310				
	CA 2226039	AA	19980706		CA 1997-2226039	19971231	<--
	BR 9800228	A	19990908		BR 1998-228	19980106	<--
	US 6048880	A	20000411		US 1998-3108	19980106	<--
	US 2002022729	A1	20020221		US 2001-918153	20010730	<--
	US 6696470	B2	20040224				
	GR 3037073	T3	20020131		GR 2001-401945	20011030	<--
PRAI	WO 1997-IB2	W	19970106	<--			
	US 1998-3108	A1	19980106	<--			
	US 1999-317570	B1	19990524	<--			
OS	MARPAT 129:108993						

GI



I

AB Title compds. [I; R1, R2 = H, halo, (substituted) (cyclo)alkyl, hydroxy(cyclo)alkyl, alkoxy, alkenyl, alkynyl, (substituted) heterocyclyl, (hetero)aryl, acyl, cyano, NO2, aminocarbonyl, etc.; R3 = (substituted) (cyclo)alkyl, (cyclo)alkylcarbonyl, cyano, formyl, alkenylcarbonyl, alkynylcarbonyl, arylcarbonyl, etc.; R4 = H, halo, alkyl, hydroxyalkyl, alkylcarbonyl, etc.; 2 of R1-R3 = atoms to form (substituted) rings; X = O, S, SO, SO2; m = 0-4; and N-oxides thereof], were prepared Thus, 3-acetyl-2,4-dimethylfuran was refluxed with NBS and AIBN in benzene for 1 h to give 88% 3-acetyl-5-bromo-2,4-dimethylfuran. The latter in dimethoxyethane was refluxed with aqueous NaHCO3 and (Ph3P)2PdCl2 followed by addition of 4-pyridineboronic acid and (Ph3P)2PdCl2 and further reflux to give 31% 3-acetyl-2,4-dimethyl-5-(4-pyridyl)furan. Selected I inhibited TNFα biosynthesis with IC50 = 100 nM to 10 μM.

ST pyridylfuran pyridylthiophene prepn TNF biosynthesis inhibitor; cell adhesion mol expression inhibitor pyridylfuran; drug pyridylfuran pyridylthiophene prepn

IT AIDS (disease)
(-related complex, drugs for; preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT Intestine, disease
(Crohn's, treatment; preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT Tumor necrosis factors

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(biosynthesis inhibitors; preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT Malaria
Malaria
(cerebral, treatment; preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT Intestine, disease
(inflammatory, treatment; preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT Cell adhesion
(inhibitors; preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT Reperfusion
(injury, treatment; preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT Brain, disease
Brain, disease
(malaria, treatment; preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT Respiratory distress syndrome
(newborn, treatment; preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT Allergy inhibitors
Anti-AIDS agents
Anti-inflammatory agents
Antiarthritics
Antiasthmatics
Anticoagulants
Antidiabetic agents
Antimalarials
Antiobesity agents
Antipyretics
Antitumor agents
Antiviral agents
Cardiovascular agents
(preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT Bone
(resorption, treatment; preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT Shock (circulatory collapse)
(septic, treatment; preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT Shock (circulatory collapse)
(toxic shock syndrome, treatment; preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT Cachexia
Keloid
Psoriasis
Sepsis
Silicosis
Skin, disease
Transplant rejection
(treatment; preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT Intestine, disease
(ulcerative colitis, treatment; preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT 210096-98-3P 210097-13-5P 210097-28-2P 210097-33-9P 210097-47-5P
210097-55-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT 207307-41-3P 210096-99-4P 210097-00-0P 210097-02-2P 210097-03-3P
210097-04-4P 210097-05-5P 210097-06-6P 210097-07-7P 210097-08-8P
210097-09-9P 210097-10-2P 210097-11-3P 210097-12-4P 210097-14-6P
210097-15-7P 210097-16-8P 210097-18-0P 210097-19-1P 210097-20-4P
210097-21-5P 210097-22-6P 210097-23-7P 210097-24-8P 210097-25-9P
210097-26-0P 210097-27-1P 210097-29-3P 210097-30-6P 210097-31-7P
210097-32-8P 210097-34-0P 210097-35-1P 210097-36-2P 210097-37-3P
210097-39-5P 210097-40-8P 210097-41-9P 210097-42-0P 210097-43-1P
210097-45-3P 210097-46-4P 210097-48-6P 210097-50-0P 210097-51-1P
210097-52-2P 210097-53-3P 210097-54-4P **210097-56-6P**
210097-57-7P 210097-58-8P 210097-59-9P 210097-60-2P 210097-61-3P
210097-62-4P 210097-63-5P 210097-64-6P 210097-65-7P
210097-66-8P 210097-67-9P 210097-68-0P 210097-69-1P 210097-70-4P
210097-71-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT 74-89-5, Methylamine, reactions 75-16-1, Methylmagnesium bromide
98-80-6, Benzeneboronic acid 103-67-3, N-Methylbenzylamine 105-53-3,
Diethyl malonate 108-30-5, reactions 108-95-2, Phenol, reactions
109-01-3, N-Methylpiperazine 110-89-4, Piperidine, reactions 110-91-8,
Morpholine, reactions 116-09-6, Hydroxyacetone 124-40-3,
Dimethylamine, reactions 367-12-4, 2-Fluorophenol 371-41-5,
4-Fluorophenol 504-02-9, 1,3-Cyclohexanedione 562-46-9,
4,4-Dimethyl-1,3-Cyclohexanedione 593-56-6, Methoxylamine hydrochloride
616-44-4, 3-Methylthiophene 638-00-6, 2,4-Dimethylthiophene 917-54-4,
Methyllithium 1194-18-9, 1,3-Cycloheptanedione 1641-09-4,
3-Cyanothiophene 1679-18-1, 4-Chlorobenzeneboronic acid 1692-15-5,
4-Pyridineboronic acid 1692-25-7, 3-Pyridineboronic acid 1765-93-1,
4-Fluorobenzeneboronic acid 1993-03-9 2713-31-7, 2,5-Difluorophenol
3172-52-9, 2,5-Dichlorothiophene 4414-45-3 5077-67-8,
1-Hydroxy-2-butanone 5720-07-0, 4-Methoxybenzeneboronic acid
6165-69-1, 3-Thiopheneboronic acid 25074-25-3 30318-99-1,
3-Bromo-4-methylthiophene 32933-07-6, 3-Acetyl-2,4-dimethylfuran
33177-29-6 36157-40-1, 3-Acetyl-2,5-dichlorothiophene 39177-23-6,
3-(4-Fluorophenoxy)phenol 41903-50-8, Hydroxyacetophenone 57248-14-3,
2,5-Dichloro-3-thiophenecarbonyl chloride 69213-94-1 69213-95-2
85006-25-3 98546-51-1 128796-39-4, 4-Trifluoromethylbenzeneboronic
acid 145129-54-0 207307-53-7 210098-25-2 210098-26-3 210098-27-4
210098-28-5 210098-30-9 210098-31-0 210098-32-1 210098-33-2
210098-34-3 210098-36-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

IT 6906-61-2P 7687-77-6P 7687-78-7P 7687-79-8P 7690-96-2P
17249-90-0P, 2,5-Dichloro-3-methylthiophene 18792-01-3P 19945-43-8P
32933-05-4P 33449-56-8P 34967-65-2P 35061-13-3P 39712-64-6P
39712-65-7P 39712-66-8P 63826-64-2P 63826-68-6P 66577-03-5P
99971-87-6P 210097-72-6P 210097-73-7P 210097-74-8P 210097-75-9P
210097-76-0P 210097-78-2P 210097-79-3P 210097-80-6P 210097-81-7P
210097-82-8P 210097-83-9P 210097-84-0P 210097-85-1P 210097-86-2P
210097-87-3P 210097-88-4P 210097-89-5P 210097-90-8P 210097-92-0P
210097-93-1P 210097-94-2P 210097-95-3P 210097-96-4P 210097-98-6P

210097-99-7P 210098-00-3P 210098-01-4P 210098-02-5P 210098-03-6P
210098-04-7P 210098-05-8P 210098-06-9P 210098-07-0P 210098-08-1P
210098-09-2P 210098-10-5P 210098-11-6P 210098-12-7P 210098-13-8P
210098-14-9P 210098-15-0P 210098-16-1P 210098-17-2P 210098-18-3P
210098-19-4P 210098-20-7P 210098-21-8P 210098-22-9P 210098-23-0P
210098-24-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bacon, E; J HETEROCYCL CHEM 1991, V28(8), P1953 HCAPLUS
(2) Gilat, S; J CHEM SOC, CHEM COMMUN 1993, 18, P1439 HCAPLUS
(3) Katritzky, A; ENERGY FUELS 1990, V4(5), P572 HCAPLUS
(4) Oda, K; J CHEM SOC, CHEM COMMUN 1994, 12, P1477 HCAPLUS
(5) Pfizer Pharma; WO 9802430 A HCAPLUS
(6) Ribereau, P; C R HEBD SEANCES ACAD SCI, SER C 1975, V280(5), P293 HCAPLUS
(7) Zhang, Y; J HETEROCYCL CHEM 1993, V30(5), P1293 HCAPLUS

IT **210097-56-6P 210097-62-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridylfurans and pyridylthiophenes as inhibitors of TNFα biosynthesis and CAMs expression)

RN 210097-56-6 HCAPLUS
CN 3-Thiophenecarboxaldehyde, 4-methyl-2,5-di-4-pyridinyl-, O-acetyloxime (9CI) (CA INDEX NAME)



RN 210097-62-4 HCAPLUS
CN 3-Thiophenecarboxaldehyde, 4-methyl-2,5-di-4-pyridinyl-, O-methyloxime, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L87 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:51800 HCAPLUS
DN 118:51800
ED Entered STN: 16 Feb 1993
TI Oxidation of carbovir, a carbocyclic nucleoside, by rat liver cytosolic enzymes. Enantioselectivity and enantiomeric inhibition
AU Patanella, James E.; Walsh, John S.

CS Res. Inst., Glaxo, Inc., Research Triangle Park, NC, USA
SO Drug Metabolism and Disposition (1992), 20(6), 912-19
CODEN: DMDSAI; ISSN: 0090-9556
DT Journal
LA English
CC 1-2 (Pharmacology)
AB Previous metabolism studies of (-)-cis-carbovir (1'R-cis-2-amino-1,9-dihydro-9-[4'S-hydroxymethyl-2-cyclopenten-1-yl]-6H-purin-6-one), an **antiviral** agent, have shown that the major route of metabolism of carbovir in the rat is oxidation of the methylene hydroxyl group of the cyclopentadiene ring to form the corresponding 4'-carboxylic acid metabolite. We have determined that rat hepatic alc. dehydrogenase and aldehyde dehydrogenase are responsible for this biotransformation through sequential oxidation of the alc. through the aldehyde to the carboxylic acid. The results of incubations of racemic (±)-cis-carbovir with rat liver cytosol showed that this oxidation occurs enantioselectively favoring the (+)-enantiomer by a factor of 6- to 7-fold. We have proven that alc. dehydrogenase contributes to the enantioselectivity of the overall oxidation process, but were unable to determine whether or not any contribution is made by aldehyde dehydrogenase. Parallel incubations conducted with the sep. enantiomers revealed that the concentration required to achieve a half-maximal rate for the oxidation of the (+)-enantiomer (0.27 mM) was one-fifth that required for the (-)-enantiomer (1.36 mM). Results from enantiomeric inhibition studies showed that (+)-carbovir inhibited the oxidation of (-)-carbovir. In contrast, (-)-carbovir did not inhibit the oxidation of (+)-carbovir.
ST carbovir oxidn liver
IT Liver, metabolism
(carbovir metabolism in, enantioselectivity and enantiomeric inhibition in)
IT 9028-86-8, Aldehyde dehydrogenase
RL: BIOL (Biological study)
(carbovir aldehyde intermediate oxidation by, enantioselectivity of)
IT 9031-72-5, Alcohol dehydrogenase
RL: RCT (Reactant); RACT (Reactant or reagent)
(carbovir oxidation by, enantioselectivity of)
IT 131956-47-3 132012-22-7 **145414-80-8 145414-81-9**
RL: FORM (Formation, nonpreparative)
(formation of, as carbovir conjugative metabolite, enantioselectivity and enantiomeric inhibition in)
IT 145414-78-4
RL: FORM (Formation, nonpreparative)
(formation of, as carbovir oxidative metabolite, enantioselectivity and enantiomeric inhibition in)
IT 118353-05-2
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metabolism of, in liver, enantioselectivity and enantiomeric inhibition in)
IT 120443-30-3, (-)-Carbovir 124915-24-8, (+)-Carbovir
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of, by alc. dehydrogenase, enantioselectivity in)
IT **145356-37-2P 145414-79-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as carbovir aldehyde intermediate trap)
IT **145414-80-8 145414-81-9**
RL: FORM (Formation, nonpreparative)
(formation of, as carbovir conjugative metabolite, enantioselectivity and enantiomeric inhibition in)
RN 145414-80-8 HCAPLUS
CN 2-Cyclopentene-1-carboxaldehyde, 4-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-, 1-(O-methyloxime), [1R-[1α(E),4α]]- (9CI) (CA INDEX NAME)



RN 145414-81-9 HCAPLUS
CN 2-Cyclopentene-1-carboxaldehyde, 4-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-, 1-(O-methyloxime), [1R-[1α(Z),4α]]- (9CI) (CA INDEX NAME)



IT **145356-37-2P 145414-79-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as carbovir aldehyde intermediate trap)
RN 145356-37-2 HCAPLUS
CN 2-Cyclopentene-1-carboxaldehyde, 4-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-, 1-(O-methyloxime), [1S-[1α(Z),4α]]- (9CI) (CA INDEX NAME)



RN 145414-79-5 HCAPLUS
CN 2-Cyclopentene-1-carboxaldehyde, 4-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-, 1-(O-methyloxime), [1S-[1α(E),4α]]- (9CI) (CA INDEX NAME)



=>